Stockwinners Market Radar for December 06, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:02 EST Five Below director sells $9.1M, CEO sells $1.9M in common stock - In a regulatory filing, Five Below disclosed that its director Thomas Vellios sold 50K shares and CEO Joel Anderson sold 10K shares of common stock on December 2nd in respective transactions of $9.1M and $1.9M.

19:58 EST AT&T COO says company continues to see healthy demand - COO Jeff McElfresh spoke today at the UBS Global TMT Conference where he provided an update to shareholders and made the following points: 1) The company continues to see healthy customer growth in its strategic focus areas of 5G and fiber as customer demand for connectivity services remains high. While the company continues to monitor the evolving economic backdrop, McElfresh noted that AT&T continues to execute well thanks to a high-quality network and a consistent go-to-market approach and additionally feels good about its ability to attract high-quality customers. 2) In addition, McElfresh added that he feels confident in the company's strong value proposition, the resilient nature of its connectivity services and the sustainability of its wireless customer growth across multiple segments. He also said that he was pleased with the results from the company's pricing actions made in the first half of 2022. 3) McElfresh said that as the company continues to lap investments made over the past two years, it is realizing additional cost efficiencies. He shared that benefits of cost reduction measures are increasingly falling to the bottom line and driving improvements in the company's operating leverage. 4) AT&T remains committed to its guidance to achieve its target of 30 million-plus locations, including business locations, with fiber by the end of 2025. At the end of the third quarter of 2022, AT&T had the ability to serve 18.5 million consumer locations and approximately 3.0 million business customer locations in more than 100 metro areas with fiber. McElfresh said that AT&T Fiber continues to deliver the best customer experience in a competitive marketplace and he's pleased with the momentum in first-year penetration rates of about two times greater than historical norms. 5) McElfresh indicated that AT&T expects full-year capital investment in the $24 billion range to meet growing demand for core connectivity, while also meeting full-year 2022 guidance for free cash flow in the $14 billion range. The company remains focused on investing in building a sustainable and durable connectivity operation with improved cash generation and continues to be pleased with the return profile of its fiber and 5G investments.

18:03 EST MediciNova presents results from subgroup analysis of Phase 2 study of MN-001 - MediciNova announced that its Chief Medical Officer, Kazuko Matsuda, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 for the treatment of hypertriglyceridemia at the International Diabetes Federation World Diabetes Congress 2022 held online December 5 - 8. In the completed Phase 2 study, MN-001 significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease and hypertriglyceridemia. Subsequent in vitro results revealed that MN-001, or tipelukast, downregulated CD36 and upregulated ABCG1 mRNA expression, both of which are highly associated with Type 2 diabetes mellitus. Hypothesizing that MN-001 might be more effective at reducing serum triglycerides in participants with a dual diagnosis of NAFLD and Type 2 diabetes mellitus, a subgroup analysis was conducted in participants with and without T2DM. Compared to subjects without T2DM, the T2DM group showed a greater reduction in serum triglyceride levels at Week 8, 50.8% reduction for with T2DM versus 17.8% reduction for without T2DM, p=0.098.

17:44 EST Bell Textron awarded $1.36B Army contract - Bell Textron was awarded a $1.36B hybrid contract for development of the Future Long Range Assault Aircraft weapon system. Bids were solicited via the internet with two received. Work has an estimated completion date of April 5, 2031. FY22 and FY23 research, development, test and evaluation, Army funds in the amount of $232.21M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:30 EST Kairos Acquisition announces liquidation - Kairos Acquisition "announced that, due to its inability to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association, the Company intends to dissolve and liquidate in accordance with the provisions of its Charter, effective as of the close of business on December 6, 2022, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.08."

17:27 EST Pulse Biosciences CFO Sandra Gardiner to resign - In a regulatory filing, the company states: "On November 30, 2022, Sandra Gardiner, CFO of Pulse Biosciences, gave notice that she was resigning from the Company. Ms. Gardiner's resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues regarding its accounting policies or practices. The Company expects to promptly begin a search for Ms. Gardiner's successor."

17:11 EST Casey's General Stores sees FY23 same-store inside sales 5%-7%. - Due to the strong year-to-date performance the Company is modifying its FY23 outlook. The Company now expects same-store inside sales to be approximately 5%-7%. Total operating expense increase is expected to be near the low end of the annual range which was approximately 9%-10%. The tax rate is now expected to be between approximately 24%-25% for the year. The Company is not updating its outlook for the following metrics. Inside margin is expected to be approximately 40%. The Company expects same-store fuel gallons to be flat to 2% higher. The Company expects to add approximately 80 stores in FY23, and expects to exceed our stated three year commitment of 345 units. Interest expense is expected to be approximately $55M. Depreciation and amortization is expected to be approximately $320 million and the purchase of property plant and equipment is expected to be approximately $450M-$500M, including approximately $135M in one-time store remodel costs for recently acquired stores.

17:02 EST Butterfly Network CEO Todd Fruchterman to depart, Rothberg named interim CEO - Butterfly Network announced that the company and Todd Fruchterman, M.D., Ph.D. have mutually agreed that Dr. Fruchterman will leave his position as President and CEO and as a member of the Board of Directors. Dr. Fruchterman will partner with Butterfly's leadership team through the end of the year to ensure a smooth transition. Dr. Rothberg will serve as Interim CEO during this time of transition and will work closely with Butterfly's executive team to continue to drive the company forward and ensure business continuity during the search for a permanent replacement.

16:46 EST Mosaic announces temporary curtailment of Canada potash mine - The Mosaic Company announced that it has temporarily curtailed production at its Colonsay potash mine in Saskatchewan. Prior o the curtailment, Colonsay had been operating at an annual run rate of 1.3M tons with plans to expand annual output to 1.8-2.0 million tonns by late 2023 following the restart of mine's second mill. With demand returning slower than expected in the second half of 2022, Mosaic's inventory levels are sufficient to meet near-term demand. Underground development work will continue in anticipation of the restart of both mills in early 2023."Our decision to temporarily curtail Colonsay reflects near-term dynamics and not long-term agricultural market fundamentals. Crop prices remain strong and continue to support healthy grower economics," said President and CEO Joc O'Rourke. "After a year of reduced applications, we believe farmers are incentivized to maximize yields, which should drive significant recovery in fertilizer demand in 2023."

16:39 EST Toll Brothers sees FY23 deliveries 8,000-9,000 units - Sees FY23 average delivered price per home $965,000-$985,000.

16:38 EST Toll Brothers sees Q1 deliveries 1,750-1,850 units - Sees Q1 average delivered price per home $950,000-$970,000.

16:34 EST Granite secures roughly $14M CMGC traffic flow improvement project - Granite announced that it has been awarded an approximately $14 million traffic flow improvement project in Santa Barbara, CA by the California Department of Transportation. This is a 'parallel project' to the Highway 101: Carpinteria to Santa Barbara suite of projects, which Granite is delivering using the innovative, collaborative Construction Manager General Contractor project delivery method. The project will be funded by the Regional Surface Transportation Program, and is expected to be included in Granite's fourth quarter CAP. The project will construct two roundabouts in the heart of Montecito's lower village. Located where busy frontage and arterial roads intersect with freeway ramps, the roundabouts will improve the traffic flow for residents and businesses. Granite's Gardner Facility will supply approximately 2,500 tons of hot mix asphalt (HMA), and all pavement and hardscape removed from the project will be recycled for use on Granite's CMGC corridor projects. The project is underway and is expected to be completed in December 2023.

16:33 EST Parts iD names James Doss as new CFO - PARTS iD "announced the appointment of James Doss as its CFO effective January 1, 2023. Doss will assume the role following the retirement of current Chief Financial Officer Kailas Agrawal at the end of this year."

16:33 EST Dogness International receives non-compliance letter from Nasdaq - Dogness announced that on December 2 it received a letter from The Nasdaq Stock Market notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550 because the closing bid price of the Company's Class A common shares was below $1.00 per share for 30 consecutive trading days. This press release is issued pursuant to Nasdaq Listing Rule 5810, which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's Class A common shares, which will continue to trade uninterrupted on Nasdaq under the ticker "DOGZ".

16:31 EST ReTo Eco-Solutions receives non-compliance letter from Nasdaq - ReTo Eco-Solutions announced that the Company received a written notification from Nasdaq Stock Market on December 1, notifying the Company that it is eligible for an additional 180 calendar day period, or until May 30, 2023, to regain compliance with Nasdaq's continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550. Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse share split, if necessary. If at any time during the Second Compliance Period the closing bid price of the Company's security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed.

16:26 EST Marathon Digital produces 472 bitcoin in November - Marathon Digital Holdings published unaudited bitcoin production and miner installation updates for November. In November, we strengthened our liquidity position, produced 472 bitcoin, and began improving the efficiency of our mining operations with new technologies," said Fred Thiel, Marathon's chairman and CEO. "Given the current macro environment, we took proactive measures to reduce our revolver borrowings from $50 million as of November 9 to $30 million as of November 30. The combination of this debt repayment and our monthly production increased our unrestricted bitcoin holdings from 1,950 BTC on November 9 to 4,200 BTC as of November 30, and we ended the month with $61.7 million in cash on hand. Our production in November was negatively impacted by curtailment at the King Mountain site in Texas. This increased curtailment was caused by spot market pricing of energy driven by weather combined with lower bitcoin prices. We are working on optimizing curtailment strategies and site operations with the new operator and expect King Mountain's productivity to improve in the coming months. While Applied Digital awaits regulatory approval to energize their facility in Garden City, Texas, construction of facilities and installations of mining servers remain underway according to the most publicly available information. Simultaneously, Marathon continues to execute on its strategy to improve how efficiently we convert electricity into value. We recently launched an immersion pilot program, and our first 14,000 S19 XPs, which are 30% more energy efficient than the prior generation of servers, were successfully installed in Applied Digital's facility in Garden City, Texas during November. We remain confident that Marathon is well-positioned to continue scaling into one of the largest and most energy-efficient operators in the industry."

16:23 EST Rani study for osteoporosis treatment RaniPill GO achieves all endpoints - Rani Therapeutics Holdings announced topline results from Part 2 of the Phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone analog PTH being developed for the treatment of osteoporosis. The study achieved all of its endpoints, with repeat doses of RT-102 being generally well tolerated and delivering drug with high reliability to participants via the RaniPill GO. "The data are highly encouraging and reinforce the tolerability and high bioavailability of RT-102 that was observed in Part 1 of the study," said Mir Hashim, PhD, Chief Scientific Officer of Rani. "The RaniPill GO capsule continues to deliver drug payloads to subjects at success rates exceeding 90%. Importantly, we believe the safety, reliability, and pharmacokinetic data that we collected through both parts of the Phase 1 study support the initiation of a Phase 2 trial of RT-102 in osteoporosis, which we anticipate beginning in the second half of 2023." "The repeat-dose data contribute to our growing body of preclinical and clinical data that we believe support the viability of the RaniPill(TM) platform to orally deliver biologics and drugs to treat chronic diseases," said Talat Imran, Chief Executive Officer of Rani. "These data give us confidence to move forward with multiple programs in parallel, including our ustekinumab biosimilar and adalimumab biosimilar programs, and to expand manufacturing scale-up. We can see a future where millions of patients no longer carry the burden of regular injections."

16:21 EST Rand Capital raises regular quarterly cash dividend 33% to 20c per share - Rand Capital announced that its Board of Directors declared a total quarterly cash dividend of $0.38 per share comprised of a $0.20 per share regular quarterly cash dividend, which was increased by $0.05 per share, and an $0.18 per share supplemental cash dividend. The dividend will be distributed on or about Friday, December 30, 2022, to shareholders of record as of Monday, December 19, 2022. At September 30, 2022, Rand had approximately 2.6 million shares outstanding. Daniel P. Penberthy, President and CEO, commented, "We continue to execute on our strategy to build a portfolio that drives growth in investment income and has enabled total dividend distributions of $0.83 in cash per share for 2022. This represents an increase of nearly 90% over our 2021 distributions. Importantly, our strong performance supports a 33% increase of our regular quarterly cash dividend to $0.20 per share, further demonstrating our ability to deliver on our goals. These are exciting times at Rand as we have the liquidity to continue to expand our portfolio, build greater earnings power while we fund lower middle market companies so they too may achieve their growth objectives."

16:16 EST SentinelOne reports Q3 ARR up 106% to $487.4M - Q3 Total customer count grew about 55% to over 9,250 customers as of October 31, 2022. Customers with ARR over $100,000 grew nearly 100% to 827 as of October 31, 2022. Dollar-based net revenue retention rate was 134%. Q3 gross margin was 64%, Non-GAAP gross margin was 71%.

16:12 EST MongoDB jumps 21% to $175 after Q3 results beat estimates, FY23 guidance raised

16:09 EST MongoDB CEO says Q3 results driven by 61% Atlas revenue growth - "MongoDB's third quarter results were highlighted by 61% Atlas revenue growth and $20 million of non-GAAP operating income. The strength in our business was driven by improved Atlas consumption trends and continued strength in new business activity. Our performance reinforces the strategic importance of MongoDB's developer data platform in enabling our customers to use software and data to transform their businesses," said Dev Ittycheria, President and CEO of MongoDB.

16:07 EST MasterCard raises quarterly dividend 16%, authorizes $9B share buyback - Mastercard announced that its Board of Directors has declared a quarterly cash dividend of 57c per share, a 16% increase over the previous dividend of 49c per share. The cash dividend will be paid on February 9, 2023 to holders of record of its Class A common stock and Class B common stock as of January 9, 2023. The Board of Directors also approved a new share repurchase program, authorizing the company to repurchase up to $9B of its Class A common stock. The new share repurchase program will become effective at the completion of the company's previously announced $8B program. As of December 1, 2022, the company had approximately $4.1B remaining under the current approved share repurchase program.

16:06 EST Pinterest announces partnership with Elliott Investment Management - Pinterest announced it has entered into a long-term cooperation agreement with Elliott Investment Management L.P., including the appointment of Marc Steinberg, Senior Portfolio Manager at Elliott, to the Board of Directors effective December 16, 2022. "We'd like to welcome Marc to the Pinterest Board following our collaborative dialogue with Marc, Jesse Cohn, and Elliott over the past few months," said Bill Ready, Chief Executive Officer, Pinterest. "We appreciate the perspective the team brings, as well as their commitment to our Company and mission. We believe in engaging our key stakeholders consistently and this one-of-a-kind agreement with Elliott is a result of that. We look forward to working together as we execute on our strategy to increase engagement with users, deepen monetization per user, and build personalized experiences on Pinterest that go from inspiration and intent to action - all while creating a more positive and inspiring place online."

16:03 EST INmune Bio to present data on INB03, trastuzumab-deruxtecan combination - INmune Bio has been invited to present data on the combination of INB03 and trastuzumab-deruxtecan, or TDxd, for treatment of HER2 positive breast cancer. The data suggests INB03, a dominant-negative TNF inhibitor that selectively sequesters soluble TNF, or sTNF, may provide a novel mechanism for reversing resistance to HER2 targeted immunotherapy, and through this mechanism, may further enhance efficacy and reduce toxicity associated with TDxd treatment in some patients. TDxd is a trastuzumab-based antibody drug conjugate used to treat certain patients with HER2 breast cancer. Mucin 4, or MUC4, an easily measured glycoprotein on the cell surface of some HER2 positive breast cancer, is a biomarker of resistance to immunotherapy, including trastuzumab, and is also a biomarker of poor survival in women with HER2+ breast cancer. Expression of MUC4 is believed to be driven by soluble TNF produced by breast cancer cells. MUC4 is at the root of therapy resistance as it causes steric hinderance and prevents binding of trastuzumab to HER2 receptors and further promotes an immunosuppressive tumor microenvironment, or TME. Schillaci has previously shown that INB03 downregulates MUC4 and reverses resistance to trastuzumab in MUC4 expressing HER2+ breast cancers. Prior to this data, it was not known if MUC4 expression by HER2 positive breast cancer has an impact on response to TDxd. Using the nude mouse model of HER2 resistance in mice with MUC4 expressing HER2+ breast cancer, JIMT-1 tumors exhibit decreased growth when treated with TDxd. The combination of TDxd with INB03 improved anti-tumor immunology of the TME with fewer myeloid derived suppressor cells and more antitumor tumor macrophages, which further decreased tumor growth compared to TDxd alone. Importantly, the addition of INB03 did not increase the toxicity of TDxd in these animals.

16:02 EST Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 - Neurocrine Biosciences announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep, or EE-CSWS. NBI-827104 was generally well tolerated.

15:48 EST Petrobras trading halted, news pending

15:08 EST Netflix CEO Sarandos sees multiple ad tiers over time - Says expects ad load to grow over time. Says "nothing to talk about yet" in terms of additional ad tiers. Says new ad tiers "open the market." Says company "really cares" about consumer choice. Comments taken from UBS Global TMT Conference.

15:03 EST Gilead announces new data from post-hoc analysis of Phase 3 TROPiCS-02 study - Gilead Sciences announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator chemotherapy in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival, or PFS, overall survival, or OS, and objective response rate, or ORR, compared with TPC across Trop-2 expression levels. Details of the late-breaking abstract will be presented today at the 2022 San Antonio Breast Cancer Symposium, or SABCS. "Sacituzumab govitecan improved both progression-free survival and overall survival in pre-treated HR+/HER2- metastatic breast cancer in the Phase 3 TROPiCS-02 study compared to standard chemotherapy options. This post-hoc analysis demonstrates that the level of Trop-2 expression on an individual's tumor did not impact sacituzumab govitecan efficacy. These data can give us confidence in the potential benefit of sacituzumab govitecan for patients with endocrine-resistant metastatic breast cancer who have progressed on available chemotherapies, across Trop-2 expression levels," said Dr. Hope Rugo, Professor of Medicine and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, U.S.

14:30 EST Forward Pharma trading resumes

14:20 EST Google makes it easier to 'dive deeper, explore topics' related to a Search - Danny Sullivan Public Liaison for Google Search blogged in part earlier: "We know what it's like to start searching for something on Google, but not really know what you're looking for - or the best way to find it. So , we're making it even easier to dive deeper and explore topics that are related to a search. You're probably familiar with how you can use filters to see just videos, news, images or shopping results on Google Search. We'll now show an easy-to-scroll list of related topics alongside these filters at the top of the search results page to help you drill down or discover something new about a specific topic. You can add or remove topics, which are designated by a + symbol, to quickly zoom in or backtrack on a search. For example, if you're searching for "dinner ideas," you might see topics like "healthy" or "easy." Tapping on a topic adds it to your query, helping you quickly refine your search results with less typing...Both topics and filters are shown in the order that our systems automatically determine is most helpful for your specific query. If you don't see a particular filter you want, you can find more using the "All filters" option, which is available at the end of the row. Animation of smartphone showing "dinner ideas" search with a user scrolling sideways through a list of filters. Over the coming days, this change will roll out for English users in the U.S. on the Google app on iOS and Android, and the mobile web." Reference Link

14:05 EST European Patent Offices' EBA denies Forward's EP2801355 petition for review - Forward Pharma (FWP) announced that the Enlarged Board of Appeal, or EBA, of the European Patent Office has denied the company's petition for review of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding. The EBA's rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the company from Biogen (BIIB) based on Biogen's future net sales of Tecfidera or other DMF products for multiple sclerosis outside the United States, as defined in the Settlement and License Agreement by and among Forward, subsidiaries of Biogen and certain other parties thereto. As previously disclosed, because the company was also unsuccessful in the U.S. Interference Proceeding after all appeals, the company will not be entitled to future royalties from the United States.

13:51 EST Vietnam-based EV maker VinFast plans for U.S. IPO - VinFast Trading & Investment announced that it has publicly filed a registration statement on Form F-1 with the Securities and Exchange Commission or SEC, relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. VinFast intends to list its ordinary shares on the Nasdaq Global Select Market under the symbol "VFS". Citigroup Global Markets Inc., Morgan Stanley , Credit Suisse and J.P. Morgan Securities will act as lead book-running managers and as representatives of the underwriters for the proposed offering. BofA Securities, Inc., BNP Paribas Securities, HSBC Securities Nomura Securities International, Inc., WR Securities and RBC Capital Markets, will also be book-running managers. Robert W. Baird & Co. Incorporated will act as co-manager for the proposed offering. Publicly listed companies in the EV space include: Tesla (TSLA), Nio (NIO), Li Auto (LI), XPeng (XPEV), ChargePoint (CHPT) , Rivian Automotive (RIVN) and Alphabet (GOOG).

13:38 EST Novartis announces results from RIGHT Choice Phase II trial of Kisqali - Novartis announced results from the RIGHT Choice Phase II trial evaluating Kisqali plus endocrine therapy against combination chemotherapy in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer, including patients with visceral crisis. Kisqali demonstrated a nearly one-year progression-free survival, or PFS, benefit in the study, "supporting the superiority of Kisqali plus ET for this hard-to-treat patient population," the company said. Data from this open-label, multi-national trial will be presented as a late-breaker oral presentation at the 2022 San Antonio Breast Cancer Symposium, or SABCS, and included in the SABCS press program. The study enrolled 222 patients with aggressive forms of HR+/HER2- MBC, including more than 50% of patients with visceral crisis as determined by investigators; Kisqali plus ET doubled the median PFS vs. combination CT at 24.0 months compared to 12.3 months in the first-line setting. Median time to treatment failure with Kisqali plus ET was 18.6 months compared to 8.5 months with combination CT. Furthermore, patients in the Kisqali plus ET arm of the trial reported lower rates of treatment-related serious adverse events and lower rates of discontinuation due to treatment-related AEs, compared to patients in the combination CT trial arm. Overall, the Kisqali safety profile was consistent with previously reported data, the company said. Jeff Legos, Executive Vice President, Global Head of Oncology and Hematology at Novartis, added: "RIGHT Choice adds to the breadth of data that supports Kisqali as the first-line treatment of choice for patients with MBC, including those with visceral crisis."

13:02 EST Apple updates App Store pricing, offers 700 new price points - Apple announced "the most comprehensive upgrade" to pricing capabilities since the App Store first launched, providing developers with 700 additional price points and new pricing tools that will make it easier to set prices per App Store country or region, manage foreign exchange rate changes, and more. Under the updated App Store pricing system, all developers will have the ability to select from 900 price points, which is nearly 10 times the number of price points previously available for most apps. This includes 600 new price points to choose from, with an additional 100 higher price points available upon request. To provide developers around the world with even more flexibility, price points - which will start as low as 29c and, upon request, go up to $10,000 - will offer an enhanced selection of price points, increasing incrementally across price ranges, the tech giant said. In each of the App Store's 175 storefronts, developers will be able to leverage additional pricing conventions, including those that begin with two repeating digits, and will be able to price products beyond $0.99 or EUR X.99 endings to incorporate rounded price ending. Starting Tuesday, developers of subscription apps will also be able to manage currency and taxes across storefronts more effortlessly by choosing a local storefront they know best as the basis for automatically generating prices across the other 174 storefronts and 44 currencies. Developers will still be able to define prices per storefront if they wish. The pricing capability by storefront will expand to all other apps in spring 2023. Periodically, Apple updates prices in certain regions based on changes in taxes and foreign exchange rates. This is done using publicly available exchange rate information from financial data providers to help ensure prices for in-app purchases stay equalized across all storefronts. Currently, developers can adjust pricing at any time to react to tax and foreign currency adjustments. Coming in 2023, developers with paid apps and in-app purchases will be able to set local territory pricing, which will not be impacted by automatic price adjustments.

12:53 EST Paccar declares 50% stock dividend, raises regular quarterly cash dividend - Paccar announced that its board of directors declared a 50% stock dividend of the company's common stock, meaning one additional share for each two shares held. The new shares will be issued on February 7, 2023, to stockholders of record at the close of business on January 17, 2023. The board of directors also declared an increase to Paccar's regular quarterly cash dividend to 25c on each newly-split share, payable on March 8, 2023 to stockholders of record at the close of business on February 14, 2023. Preston Feight, CEO, noted, "Paccar has invested $7.3 billion in new and expanded facilities, innovative products and new technologies during the past decade. These investments have created an industry-leading truck range that delivers excellent fuel efficiency and low operating costs."

12:42 EST Paccar declares extra cash dividend of $2.80 per share - Paccar announced that its board of directors declared an extra cash dividend of two dollars and eighty cents per share, payable on January 5, 2023, to stockholders of record at the close of business on December 16, 2022. Mark Pigott, executive chairman, shared, "Paccar has generated excellent shareholder returns and annual net income due to its industry-leading premium quality vehicles, strong growth of its aftermarket parts and financial services, and innovative use of technology to enhance customers' operational performance."

12:18 EST Doma Holdings trading resumes

12:03 EST Natures Sunshine Products appoints Shane Jones as CFO - Nature's Sunshine Products announced that Shane Jones has been named CFO, effective December 30, 2022. Jones joins Nature's Sunshine from FullSpeed Automotive, where he served as the company's CFO. Jones will report directly to the CEO and serve as a key member of the Company's Executive Committee. He will also work closely with the company's Operating Business Units, IT, and Supply Chain team to identify operating efficiencies and drive sustainable, profitable growth. Jonathon Lanoy, the Company's interim CFO since September 6, 2022, will continue as Senior Vice President of Finance and Corporate Controller. He will also serve as a member of the Company's Executive Committee.

12:00 EST NRG Energy falls -13.9% - NRG Energy is down -13.9%, or -$5.69 to $35.16.

12:00 EST Signet Jewelers rises 19.9% - Signet Jewelers is up 19.9%, or $11.48 to $69.31.

12:00 EST Vivint Smart Home rises 32.3% - Vivint Smart Home is up 32.3%, or $2.90 to $11.89.

11:50 EST Doma Holdings trading halted, news pending

11:02 EST JetBlue announces strategy to achieve Net Zero by 2040 - JetBlue announces a science-based target approved by the Science Based Targets initiative, a coalition that defines and promotes best practices in emissions reduction targets. With this target, JetBlue commits to reducing well-to-wake scope 1 and 3 greenhouse gas emissions related to jet fuel by 50% per revenue tonne kilometer by 2035 from a 2019 base year. JetBlue's most aggressive near-term emissions reduction target to-date, this science-based target aligns with the goals of the Paris Agreement and the growing airline's own goal to reach net zero carbon emissions by 2040 - 10 years ahead of broader airline industry targets. Aligned with SBTi requirements, JetBlue will also regularly review and update this target following any significant change to JetBlue's business or structure. To meet this aggressive near-term target, the airline will increase its investments in lower-carbon solutions within its operation and will evaluate future sustainability investments with its science-based target in mind. JetBlue also recognizes how critical external partners are to decarbonizing the aviation industry and is committed to encouraging and supporting efforts by aircraft and engine manufacturers, governments, regulatory agencies, and fuel suppliers to realize their own GHG emission reduction goals.

10:55 EST American Express CEO says mid-teens revenue growth in 2023 'very probable' - American Express CEO Stephen Squeri said while presenting at the Goldman Sachs Financial Services Conference: "Well, I mean, look, we've had 6 straight quarters of 24% revenue growth, so that will give you a little bit of confidence. But I think everything that I just said -- and we're staying focused, we're staying focused as a company. I think our business is a lot stronger after the pandemic than it was pre-pandemic. I think we learned a lot. We invested a lot in our customers. We've changed our model in terms of retention. We've changed value propositions, and we stood by our customers. And they've rewarded that with higher spending and more engagement. And so for everything I just said gives me the confidence that, that 10% in 2024 is possible. And as we said sort of mid-teens revenue growth in 2023, we think is very probable. So in each of the presentations that we've had thus far, there's obviously been discussions about a lot of uncertainty as it pertains to '23, particularly in the back half, your customer base is obviously a bit unique, but you're talking about revenue growth, as you just said mid-teens for next year... I mean, we still see record months for us. And obviously, I think you will see year-over-year deceleration because last year, what happened at this time, you were starting to see growth. And -- but overall, the consumer is strong. Small businesses continue to be strong for us. International is strong. And I'm talking about 2 months months in here. We're talking about October and November. And so we're really pleased with the momentum that we've seen, and we're not seeing any change in sort of that credit profile. What you have seen is you've seen some small businesses that have slowed down some of their advertising spending, you've heard about retailers talking about a decrease in sort of discretionary spending. But these are small sort of hits to our business at this particular point in time. And and just looking at October and November, results are exactly what we would have expected and very, very strong at this point."

10:42 EST Nordstrom falls 4% to $18.53 after Morgan Stanley conference presentation

10:22 EST Pacifico Acquisition Corp trading resumes

10:17 EST Pacifico Acquisition Corp trading halted, volatility trading pause

10:13 EST PhenixFIN trading halted, volatility trading pause

10:06 EST Apple's Self Service Repair now available in eight European countries - Apple announced Self Service Repair is now available in eight European countries, providing repair manuals and genuine Apple parts and tools through the Apple Self Service Repair Store. Customers who wish to complete their own repairs will be able to perform many of the most common repairs for the iPhone 12 and iPhone 13 lineups, and Mac notebooks with Apple silicon. The Self Service Repair Store provides access to more than 200 individual parts and tools, as well as repair manuals. The program enables customers who are experienced with the complexities of repairing electronic devices the opportunity to complete their own repairs, using the same manuals, parts, and tools as Apple Store locations and Apple Authorized Service Providers. Self Service Repair is part of Apple's efforts to further expand access to repairs and increase repairability of products over time. Reference Link

10:05 EST Winc Inc trading resumes

10:02 EST Apple announces Apple Music Sing feature - Apple announced Apple Music Sing, a new feature that allows users to sing along to their favorite songs with adjustable vocals and real-time lyrics. Apple Music Sing offers multiple lyric views to help fans take the lead, perform duets, sing backup, and more - all integrated within Apple Music's unparalleled lyrics experience. Coupled with an ever-expanding catalog that features tens of millions of the world's most singable songs, Apple Music Sing makes it fun and easy for anyone to participate, however and wherever they choose. Apple Music Sing will be available later this month to Apple Music subscribers worldwide, and can be enjoyed on iPhone, iPad, and the new Apple TV 4K.

10:00 EST NRG Energy falls -10.0% - NRG Energy is down -10.0%, or -$4.07 to $36.77.

10:00 EST Studio City rises 13.7% - Studio City is up 13.7%, or 45c to $3.74.

10:00 EST Vivint Smart Home rises 32.2% - Vivint Smart Home is up 32.2%, or $2.90 to $11.88.

09:54 EST Meta's Oversight Board urges increased transparency around cross-check - The Meta Oversight Board said, "To comply with Meta's human rights commitments and address these problems, a program that corrects the most high-impact errors on Facebook and Instagram should be structured substantially differently. The Board has made 32 recommendations in this area.. As Meta seeks to improve its content moderation for all users, it should prioritize expression that is important for human rights, including expression which is of special public importance. Users that are likely to produce this kind of expression should be prioritized for inclusion in lists of entities receiving additional review above Meta's business partners. Posts from these users should be reviewed in a separate workflow, so they do not compete with Meta's business partners for limited resources. While the number of followers can indicate public interest in a user's expression, a user's celebrity or follower count should not be the sole criterion for receiving additional protection. If users included due to their commercial importance frequently post violating content, they should no longer benefit from special protection. Radically increase transparency around cross-check and how it operates. Meta should measure, audit, and publish key metrics around its cross-check program so it can tell whether the program is working effectively. The company should set out clear, public criteria for inclusion in its cross-check lists, and users who meet these criteria should be able to apply to be added to them. Some categories of entities protected by cross-check, including state actors, political candidates and business partners, should also have their accounts publicly marked. This will allow the public to hold privileged users accountable for whether protected entities are upholding their commitment to follow the rules. In addition, as around a third of content in Meta's cross-check system could not be escalated to the Board as of May-June 2022, Meta must ensure that cross-checked content, and all other content covered by our governing documents, can be appealed to the Board. Reduce harm caused by content left up during enhanced review. Content identified as violating during Meta's first assessment that is high severity should be removed or hidden while further review is taking place. Such content should not be allowed to remain on the platform accruing views simply because the person who posted it is a business partner or celebrity. To ensure that decisions are taken as quickly as possible, Meta should invest the resources necessary to match its review capacity to the content it identifies as requiring additional review." Reference Link

09:49 EST Visteon announces collaboration with Amazon Web Services - Visteon (VC) announced a collaboration with Amazon Web Services (AMZN) that will deliver Visteon's pioneering AllGo connected vehicle technology utilizing AWS world-class cloud capabilities. AWS has been the world's most comprehensive and broadly adopted cloud offering for over 15 years. Visteon is the industry leader in cockpit electronics and connected vehicle technology. Visteon's AllGo connected services powered by AWS are expected to deliver value to constituents in every facet of the automotive industry, including manufacturers, vehicle app developers and consumers. The collaboration utilizes multiple AWS technology solutions across IoT, storage, and compute categories and a fast, secure cloud environment to handle critical connected vehicle activities and create the car's own digital ecosystem.

09:47 EST NRG Energy falls -11.7% - NRG Energy is down -11.7%, or -$4.77 to $36.07.

09:47 EST Perfect Corp. rises 10.4% - Perfect Corp. is up 10.4%, or 60c to $6.38.

09:47 EST Vivint Smart Home rises 32.3% - Vivint Smart Home is up 32.3%, or $2.90 to $11.89.

09:45 EST G-III Apparel CEO buys $3.14M in common stock - In a regulatory filing last night, G-III Apparel disclosed that its CEO Morris Goldfarb bought 250K shares of common stock on December 5th in a total transaction size of $3.14M. Shares of G-III Apparel are up about 8% in early trading at $13.21.

09:43 EST Sunrise New Energy receives $464M purchase order - Sunrise New Energy announced that it has received a purchase order from a top 5 global EV battery manufacturer for 80,000 metric tons of graphite anode. The purchase order is for 80,000 tons of graphite anode over 2 years. The approximate value of the purchase order based on current pricing is $464M. The company anticipates that it will begin recognizing significant revenue related to this purchase order in February of 2023 as additional production capacity comes online. As part of the validation process, the customer received shipment of an initial order and was very satisfied with the quality of the graphite anode. The customer also has had a senior scientist on site for the last several weeks at Sunrise New Energy's manufacturing plant in Guizhou Province. The scientist has investigated the manufacturing methods and quality control as well as tested the finished product of the plant on an ongoing basis and has given the company top marks on his assessment.

09:34 EST G-III Apparel CEO buys $3.14M in common stock - In a regulatory filing last night, G-III Apparel disclosed that its CEO Morris Goldfarm bought 250K shares of common stock on December 5th in a total transaction size of $3.14M. Shares of G-III Apparel are up about 8% in early trading at $13.21.

09:32 EST OLB Group initiates purchasing shares under 1M share buyback program - OLB Group announced that the company has initiated purchasing of shares in the open market under the previously announced share repurchase program of up to 1 million shares of its outstanding shares of common stock. Ronny Yakov, CEO of OLB Group, said, "Our Board of Directors has authorized this stock buyback to exercise our financial flexibility to buy our common stock from time to time as market conditions warrant. With no outstanding corporate debt and a historically low market valuation of approximately 0.25 times projected 2022 revenue of over $32 million, the company sees an opportunity to reduce its shares outstanding at very attractive valuations. Last week, we retained a broker dealer to purchase shares in the open market and will continue to do so on an ongoing basis to enhance shareholder value."

09:31 EST Verra Mobility, Car IQ announce partnership - Car IQ announced a partnership with Verra Mobility that will expand the company's current offerings beyond fuel payments to provide fleet customers with a complete toll payment suite. Car IQ's partnership with Verra Mobility will allow fleets to seamlessly connect with tolling solutions via Verra Mobility's extensive network and pay without the use of a credit or debit card. With Car IQ Pay fleets will now have a simplified and unified billing platform that facilitates payment of multiple types of services supporting a fleet company's back-end accounting systems. Car IQ will now offer new payment services that provide toll violation protection for vehicles that do not normally use tollways by registering license plates nationally with toll agencies and managing the on-time, direct payment of a fleet's tolls, to avoid violations, penalties or additional fees from a managing toll agency. Car IQ continues to innovate across all payment categories and this partnership will enable fleets to connect, without the use of a credit card, to toll management platforms created and managed by Verra Mobility.

09:22 EST Gores files preliminary proxy statement for holder approval to liquidate in 2022 - Gores Holdings VIII, announced that on December 5 , the Company filed a preliminary proxy statement to seek stockholder approval to adopt an amendment to its Amended and Restated Certificate of Incorporation to allow the Company to redeem all of its outstanding public shares and liquidate before December 31 , in advance of the automatic termination date in its current Charter of March 1. Following the termination of the Company's Agreement and Plan of Merger with Footprint International Holdco, the Company believes that consummation of a suitable merger is highly improbable. Furthermore, because redemptions made after December 31 may be subject to a 1% excise tax included as part of the Inflation Reduction Act of 2022, it is in the best interest of the Company's stockholders to return the cash in trust within calendar year 2022 rather than wait for expiration in 2023."We remain active in SPACs and continue to be committed to the SPAC product in the long-term," said Alec Gores, Chairman and CEO of The Gores Group. "The current market environment has informed our view that liquidating any imminently expiring vehicles and returning capital to our stockholders as soon as possible is the best course of action. We look forward to continuing to leverage the SPAC product to assist quality companies in raising capital and becoming publicly listed during 2023 and beyond."

09:16 EST Cassava Sciences completes dosing in open-label study of simufilam - Cassava Sciences announced the completion of drug administration in an open-label study of simufilam for Alzheimer's disease. This study was designed to evaluate long-term drug safety and to measure cognitive changes over 12 months in approximately 200 patients with mild-to-moderate Alzheimer's disease treated with open-label simufilam 100 mg twice daily. Simufilam is Cassava Sciences' oral drug candidate for Alzheimer's disease dementia. To ensure the highest integrity of data analysis, outside biostatisticians with specific expertise in Alzheimer's disease will conduct an independent statistical analysis on the clinical dataset. Cassava Sciences may announce study results approximately year-end 2022, pending completion of a study report by outside biostatisticians.

09:15 EST Bonum Health signs telemedicine services deal with independent GPO - TRxADE HEALTH announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a preferred telemedicine services agreement with an independent group purchasing organization which will provide deep discounts to access Bonum Health's service platform for 100+ pharmacies and their patient's in the northeastern part of the United States.

09:11 EST Titan Medical U.S. subsidiary temporarily furloughs 40 employees - Titan Medical announced the company will implement certain cost-cutting measures with a view to preserving capital to support the strategic review process announced on November 30, 2022 while allowing the company to continue working on the investigational device exemption filing with the U.S. Food and Drug Administration. As part of this plan, the company's U.S. subsidiary will be temporarily furloughing approximately 40 employees at its Chapel Hill, North Carolina facility effective immediately. "While the company works through the strategic review process, and in view of the company's capital position and the challenging market conditions, we have had to make the extremely difficult decision to place some of our employees on furlough," said Cary Vance, Titan's President and CEO. "These employees have made valuable contributions to the development of robotic assisted technologies, and as we have communicated to the impacted employees, we look forward to bringing our employees back to work if and as soon as we are able. While this is not the news we would want to have been sharing, it is a necessary measure that allows us to strategically maintain a workforce that supports the strategic review process while continuing to make progress towards an IDE filing." With this announcement, the company will limit work to tasks related to the strategic review process, the IDE filing and fulfilling certain other contractual development and supply obligations. The cost-cutting measures will impact the timing and costs of the company's milestones and the company is therefore withdrawing all forward-looking statements included in its continuous disclosure documents and other documents filed on SEDAR or EDGAR with respect to the cost and timing of the development of its Enos surgical system.

09:11 EST Verizon brings high-speed fiber internet to more Massachusetts customers - Verizon is bringing high-speed fiber internet to customers across the state of Massachusetts, including Worcester, Brockton, Lowell, Everett, Milton, Newburyport and Plainville. The latest Verizon Home Internet expansion is expected to make Verizon's 100% fiber optic network available to over 70,000 additional homes and businesses in the Bay State. "Verizon is focused on delivering broadband internet service, and the major economic benefits associated with it, to the people of Massachusetts," said Kevin Service, Senior Vice President of Wireline Network Operations for Verizon. "From Fios to 5G Home, more Verizon customers than ever across the Bay State have access to high-speed internet to fuel how they work, live and play."

09:10 EST EnWave signs Technology Evaluation, License Option Agreement with egg supplier - EnWave announced that the Company has signed a Technology Evaluation and License Option Agreement with one of the largest foodservice suppliers of egg products in the United States. During the term of the Agreement, the Partner will lease a pilot-scale vacuum-microwave machine to facilitate in-house product development, with a focus on shelf-stable meals, snacks and functional ingredients. EnWave will collaborate with the Partner to ensure best practices developed over two decades of commercial vacuum-microwave experience are used during this new product development program. The Agreement also provides the Partner with the right to license EnWave's proprietary vacuum-microwave technology for the production of egg and egg-based applications. EnWave has completed significant internal research and development to highlight the benefits of using its patented Radiant Energy Vacuum technology in several food categories. The Agreement with the Partner is the first that is focused primarily on egg and egg-based applications. To date, the Company has signed more than fifty licenses with companies spanning twenty countries globally.

09:08 EST Professional Diversity Network launches Alpha Phi Alpha job board - Professional Diversity Network announced its launch of the Alpha Phi Alpha Fraternity, Inc. job board https://apajobs.com/, a fully integrated job board located on APA's website. Alpha Phi Alpha is the largest historically black fraternity.

09:08 EST Priceline launches strategic partnership with British Airways, Iberia - Priceline announced a New Distribution Capability agreement with British Airways and Iberia, part of International Airlines Group. The NDC partnership will allow travelers searching and booking on Priceline to gain access to the airline group's full range of fares and additional product offerings, including flexible booking options and ancillaries, such as seat selection and checked bags. The new strategic partnership also extends across Priceline's parent company, Booking Holdings, including Agoda, who continues to strengthen its flight and connected trip proposition within the Asia Pacific region.

09:07 EST Alight acquires ReedGroup, financial terms not disclosed - Alight announced it has acquired ReedGroup, an expert in leave management solutions from The Guardian Life Insurance Company of America. Alight's platform strategy, underpinned by Alight Worklife is focused on improving the employee experience while driving measurable outcomes for companies and their people. The acquisition of ReedGroup builds upon Alight's strategy to support employees and their dependents from hire through retire by adding new content, capabilities and products that have the power to change the way that people interact with HR, their benefits and their employer to power more confident decisions for life. "Combining the strength of ReedGroup with Alight's full breadth of capabilities will create a more effective leave experience for both employers and employees," said Andre Walton, executive vice president, insurance solutions at Alight. "When Alight supports workers through their leave with clinical guidance and expert second opinion services and more, we can help workers care for their health and wellbeing during their time on leave and return to work with a thoughtful eye towards improving outcomes for workers and for their employers."

09:06 EST Muscle Maker announces it has crossed the milestone of 50 franchise agreements - Pokemoto, Muscle Makeray announced it has crossed a threshold milestone of 50 franchise agreements signed, reaching 15 states once opened, since putting its foot on the gas with franchising efforts. Pokemoto will make a splash in new markets while expanding in existing markets, including Texas, South Carolina, New Jersey, Connecticut, Massachusetts, Rhode Island, Florida, Kansas, Maryland, Virginia, New York, Pennsylvania, Mississippi, Tennessee and Georgia. Specific location details can be found on the Pokemoto website - www.Pokemoto.com/locations. "Achieving 50 franchise agreements signed for a relatively young brand is a major accomplishment for our team" said Michael Roper, CEO of Pokemoto. "The team has been working tirelessly to keep the momentum going as we near the year's end. Franchise sales efforts are set on seeking out entrepreneurs looking to be a part of something fresh and new to the restaurant space; an opportunity outside of your standard burger, pizza and salad concepts. We believe we have a unique opportunity with a trending food concept that boasts "healthier for you" benefits, a low cost of entry and ease of operations. Seeing our footprint grow shows that our franchise marketing efforts are working and that we're resonating with the right audiences. We continue to seek out new partnerships, vendors and resources to expand our tool kit for prospective and current franchisees so that they can focus their efforts on expanding their Pokemoto portfolios."

09:05 EST Sorrento Therapeutics receives FDA clearance to initial trials with STI-1557 - Sorrento Therapeutics has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants. This mRNA vaccine incorporates a mutation in the furin cleavage site that prevents the S1 subunit cleavage from the spike protein from anchoring on the muscle cell membrane. This modification was introduced to prevent the leakage of S1 subunit from the expressed spike protein into the blood circulation, which is known in part to potentially cause undesirable side effects in vital organ tissues following administration of the current FDA-approved mRNA vaccines. The mRNA is encapsulated in a Sorrento proprietary lipid nanoparticle formulation to protect mRNAs from degradation and enable potent translation of the S protein in host cells after intramuscular delivery, thus inducing an adaptive immune response. The preclinical work that supported this investigational new drug application has been published online in Molecular Therapy Nucleic Acids, a Cell Press partner journal. The paper, titled "Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants," will appear in print in the December 2022 issue of the journal.

09:05 EST California Water Service appoints Thomas Scanlon as corporate controller, PAO - California Water Service Group announced the promotion of Thomas Scanlon to Corporate Controller and Principal Accounting Officer and Justin Skarb to Vice President, Government & Community Affairs, effective January 1, 2023. Before joining California Water Service Group as Director of Financial Reporting in 2010, Scanlon served as Subsidiary Controller at Sun Power Systems Corporation. He will succeed David B. Healey, who is retiring after 13 years of service. Skarb began his career at the company in 2009 in the newly created role of Government & Community Relations Manager and was promoted to Director of Community Affairs & Government Relations in 2017.

09:04 EST Sweetgreen COO Chris Carr to depart, Stephanie Traut to oversee operations - Sweetgreen announced that Chris Carr, COO, will be departing the company for personal reasons on March 17, 2023. In the first quarter of 2023, Chris will stay on in an advisory capacity. Effective January 1, 2023, Stephanie Traut, SVP of operations, will oversee operations reporting directly to Jonathan Neman. Traut joined sweetgreen in August 2021 bringing over 20 years of operational leadership.

09:03 EST LitePoint joins O-RAN ALLIANCE - LitePoint announced its membership in the O-RAN ALLIANCE, to enable an ecosystem of mobile operators, wireless infrastructure vendors and core network products and solutions that will bring speed and bandwidth of 5G networks to more parts of the world. The O-RAN ALLIANCE is a global community dedicated to developing and promoting open Radio Access Network products and solutions for mobile networks. With more than 300 members, the O-RAN ALLIANCE is enabling the industry to re-shape RANs to be more intelligent, open, virtualized and fully interoperable.

09:02 EST Lightspeed names Kady Srinivasan as Chief Marketing Officer - Lightspeed announced that the company has appointed Kady Srinivasan, former Klaviyo and Dropbox executive, as its Chief Marketing Officer, reporting to JP Chauvet, CEO of Lightspeed. Srinivasan joins Lightspeed from Klaviyo, a SaaS marketing automation technology provider, where she served as SVP, Global Head of Marketing.

08:57 EST Soluna Holdings: Dorothy project makes progress with regulatory process - Soluna Holdings is providing the following corporate update. The company's Dorothy project, a 50MW facility in Texas continues to make steady progress through the regulatory process. The project is nearing the completion of the planning phase and will then advance into the modeling phase. The modeling phase is scheduled to complete in February when the project enters the operations phase where the logistics of a specific date for energization of the facility are set. This would put the project on track to begin energizing in the first quarter of 2023. The grid system operator, wind farm, and Soluna must coordinate physical logistics and other requirements as they drive to energize the site. Current target dates range from early February to early March as work is completed to integrate the facility with the grid. Michael Toporek, CEO of Soluna Holdings, stated, "Through the market turbulence, we have remained focused to get Project Dorothy through the approval process. By working collaboratively with Texas regulators, the utilities, and the owner of the wind farm, we now have a clear path to energize the first 50MW of our Project Dorothy data center in Texas. We fundamentally believe Bitcoin and other intensive computing can be a major catalyst for the renewable energy industry, and this project will be a repeatable blueprint for future projects."

08:53 EST Jupiter Wellness gives corporate update including launch of clinical trials - Jupiter Wellness issued a Letter to Shareholders today to provide a corporate update since its last report in September. that letter said, in part: "I would like to take this opportunity to review the significant progress made by your company since the last Letter to Shareholders dated September 15. We have launched or restarted two clinical trials for tinnitus and eczema, both conditions with large patient populations. We have entered the potentially lucrative market of Female Sexual Wellness and obtained or added to our intellectual property portfolio with the addition of our hair loss therapy. We finally had our topical treatment for psoriasis and vitiligo approved by the "FDA of India" and just announced the market launch in India. And lastly, we announced record revenues for the Nine Months ending September 30 vs. the corresponding period in 2021.We have compiled a quick summary of recent developments and an overview of our products and their current disposition - whether already on the market and generating revenues, currently in clinical trials, or in development.":

08:52 EST Jupiter Wellness looking forward 'to capitalizing on progress' - Jupiter Wellness issued a Letter to Shareholders to provide a corporate update since its last report in September. CEO Brian John said, in part, " I would like to take this opportunity to review the significant progress made by your company since the last Letter to Shareholders dated September 15. We have launched or restarted two clinical trials for tinnitus and eczema, both conditions with large patient populations. We have entered the potentially lucrative market of Female Sexual Wellness and obtained or added to our intellectual property portfolio with the addition of our hair loss therapy. We finally had our topical treatment for psoriasis and vitiligo approved by the "FDA of India" and just announced the market launch in India. And lastly, we announced record revenues for the Nine Months ending September 30 vs. the corresponding period in 2021...As we head into the end of 2022, we look forward to capitalizing on the progress we have made in building a foundation for continued revenue growth, monetizing our clinical trial programs, building profitability, and enhancing shareholder value."

08:48 EST Tigo Energy to become public through Roth CH Acquisition IV combination - Tigo Energy and Roth CH Acquisition IV (ROCG) announced the signing of a definitive agreement for a business combination that is expected to result in Tigo becoming a public company. Upon closing of the transaction, subject to approval by ROCG's stockholders and other customary requirements, the combined company will be named Tigo Energy and is expected to list on Nasdaq under the ticker symbol (TYGO). Current Tigo CEO and chairman, Zvi Alon, will continue to lead the company along with the current management team, and existing Tigo stockholders will roll 100% of their equity into the company. The transaction is expected to close in the second quarter of 2023. Pursuant to the business combination agreement, ROCG will acquire Tigo for a pre-money equity value of $600M. In connection with the transaction, ROCG will issue 60M newly issued shares to current stockholders of Tigo. Existing Tigo stockholders will not receive any cash proceeds as part of this transaction and will roll 100% of their equity into the company. Assuming no ROCG stockholders exercise their redemption rights, gross proceeds of approximately $117M will be released to the company from the trust account in connection with the transaction. The boards of directors of Tigo and ROCG have unanimously approved the transaction. The transaction will require the approval of the stockholders of ROCG and is subject to other customary closing conditions. The transaction will also require the approval of the stockholders of Tigo by written consent or at a meeting of the stockholders of Tigo. The transaction is expected to close in the second quarter of 2023. Upon closing of the transaction, Tigo's senior management will continue to serve in their current roles. Current Tigo stockholders will retain approximately 82% of the ownership at close of the company, assuming no ROCG stockholders exercise their redemption rights.

08:46 EST Rackspace reports ransomware incident isolated to Hosted Exchange business - Rackspace Technology announced a ransomware incident affecting its Hosted Exchange environment, which is causing service disruptions for the company's Hosted Exchange customers. Alongside the Rackspace Technology internal security team, the company has engaged a leading cyber defense firm to investigate. Immediately upon detecting the incident, the company took proactive measures to isolate the Hosted Exchange environment to contain the incident. Based on the investigation to date, Rackspace Technology believes that this incident was isolated to its Hosted Exchange business. Rackspace Technology's other products and services are fully operational, and the company has not experienced an impact to its Email product line and platform. Out of an abundance of caution, Rackspace Technology has put additional security measures in place and will continue to actively monitor for any suspicious activity. Rackspace Technology is in ongoing communication with Hosted Exchange customers to help them migrate to a new environment as quickly as possible. Rackspace Technology has surged support staff and will be taking additional steps to help guide customers through this process in order to limit the impact to their own operations. Although Rackspace Technology is in the early stages of assessing this incident, the incident has caused and may continue to cause an interruption in its Hosted Exchange business and may result in a loss of revenue for the Hosted Exchange business, which generates approximately $30 million of annual revenue in the Apps & Cross Platform segment. In addition, Rackspace Technology may have incremental costs associated with its response to the incident. Rackspace Technology continues to investigate the incident. Beginning on December 2, 2022, the company issued service announcements on its website with details relating to the foregoing incident and will continue to post updates on its website as warranted.

08:44 EST Emcore introduces new TAC-450 Inertial Measurement Units - EMCORE Corporation announced the introduction of the TAC-450 line of Inertial Measurement Units, which includes three high-performance IMUs with tactical-grade photonic Fiber Optic Gyros, and features EMCOREs patented Photonic Integrated Chip technology. The EMCORE TAC-450 line of IMUs are offered in a compact housing resulting in a smaller, lighter package that expands the types of potential autonomous applications that can use EMCORE's new IMU technology. The PIC Inside design with lower power electronics also delivers exceptional product life and reliability with outstanding shock/vibration tolerance. Each TAC-450 IMU offers dynamic and precise sensor performance providing exceptional navigation capability and environmental robustness for challenging applications.

08:43 EST Global Tech retains ShareIntel-Shareholder to assist Christian Levine Law - Global Tech Industries Group announced today that its board of directors approved and instructed management to negotiate and execute a service agreement with ShareIntel-Shareholder Intelligence Services to further assist The Christian Levine Law Group, as well as Warshaw Burstein, LLP, each already retained by the Company, to review the trading history of the Company's common stock for the past two years. ShareIntel offers unprecedented access and insight into broker-dealer, clearing firm and shareholder position movement. ShareIntel utilizes a patented process called DRIL-Down to aggregate and analyze repository data from reporting entities, broker-dealers and shareholders enabling Global Tech Industries to track shareholder ownership, identify parties to suspicious, aberrant or unusual trading activity and deploy corrective action steps to help curtail such activity. The Christian Levine Law Group, LLC has been pursuing investment banking and brokerage firms on Wall Street for over 20 years for illegal naked short selling, which is a sophisticated form of stock manipulation. The Company believes it may have been the target of a market manipulation scheme involving illegal naked short selling of its common stock over the last two years and has decided to investigate and expose any wrongdoing.

08:42 EST Quantum Computing partners with Rabobank to fight fraud - Quantum Computing announced that it will work together with Rabobank for a project to demonstrate the application of its photonic quantum information technologies, including the Dirac 1 entropy quantum computing system, to fraud detection. Rabobank is adding QCI to its arsenal of existing fraud detection techniques and solutions because it is committed to protecting its customers against costly fraudulent transactions.

08:41 EST STRONG/MDI Screen Systems signs screen supply agreement with Marcus Theatres - STRONG/MDI Screen Systems, a wholly-owned subsidiary of Ballantyne Strong, announced it has signed an exclusive three-year cinema screen supply agreement with Marcus Theatres. Ray Boegner, President of Strong Entertainment, commented, "We are pleased to continue our long-running partnership with Marcus Theatres, helping them provide a premium cinema experience to their customers in their theatres across the United States. We continue to partner with leading cinemas to provide them with the best in projection screen quality and technology, and we look forward to expanding our partnership network as more and more cinemas throughout the U.S. and globally look to upgrade their offerings."

08:40 EST Albireo Pharma appoints Streck as CMO, Hopkinson to board of directors - Albireo Pharma (ALBO) announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively. These appointments coincide with an important time for Albireo as the Company continues to deliver on clinical, regulatory, and commercialization milestones for Bylvay for indications potentially across three pediatric cholestatic liver diseases while advancing investigational compounds for adult liver and viral diseases. As the Chief Medical Officer, CMO, Dr. Streck will join the Albireo Enterprise Leadership Team and will be responsible for providing vision, leadership, and expertise for the Company's next growth phase, necessary to shape and enhance the CMO organization within a fully realized biopharmaceutical company. Most recently, Dr. Streck served as Chief Medical Officer at Arena Pharmaceuticals. As a member of the Albireo Board of Directors, Dr. Craig Hopkinson brings more than 25 years of experience building and leading clinical development organizations and medical affairs groups. Dr. Hopkinson currently serves as Executive Vice President of Research & Development and Chief Medical Officer at Alkermes (ALKS).

08:39 EST Robinhood opens waitlist for 'Robinhood Retirement' product - In a blog post, Robinhood stated: "Starting December 6, everyone will be able to sign up for Robinhood Retirement waitlist to invest for their future the Robinhood way - no employer necessary. All while earning a 1% match from Robinhood on every eligible contribution dollar, other fees may apply. With Robinhood Retirement, customers are now able to open multiple Robinhood accounts for the first time." Reference Link

08:38 EST QuickLogic signs eFPGA IP partnership agreement with Yu-Hsin Layout Technology - QuickLogic announced that it has signed an embedded FPGA IP agreement with Yu-Hsin Layout Technology, based in Zhubei City, Taiwan. This agreement allows Yu-Hsin to utilize QuickLogic's eFPGA IP technology to add eFPGA integration to their wide array of design services. The agreement is effective immediately and QuickLogic's eFPGA IP technology is available now, enabling Yu-Hsin to quickly and easily target eFPGA IP to nearly any foundry and process node for fast and efficient SoC integration.

08:36 EST Edible Garden expands distribution with Gristedes, D'Agostino supermarkets - Edible Garden announced an expansion of its distribution with Gristedes and D'Agostino supermarkets to sell Edible Garden products in 29 of their combined locations in Manhattan, Brooklyn and Westchester. In addition to an expansion of the distribution network, Edible Garden plans to collaborate with Gristedes and D'Agostino on the display and strategic placement of Edible Garden's products within their retail locations, utilizing advanced analytics and time-tested merchandising techniques. New branded displays will be set up with the products at strategic locations within the stores. In addition, Edible Garden will work with their buying teams to determine the appropriate, optimized, SKU mix for each of the retail locations. Products will include all varieties of 4" potted herbs, hydro basil, butterhead lettuce and all varieties of cut herbs in bags to preserve their freshness.

08:36 EST Sellas Life Science's GFH009 selected for PIVOT program - SELLAS Life Sciences announced that SELLAS' highly selective CDK9 inhibitor, GFH009, will be evaluated in pediatric solid tumors and leukemia models through the National Cancer Institute Pediatric Preclinical in Vivo Testing Program. GFH009 testing through the program involves a two-phase research plan for pharmacokinetics (PK) and efficacy in pediatric tumors. In the first phase, PIVOT principal investigators will conduct PK experiments to confirm the appropriate dose and route administration for GFH009. In the second phase, monotherapy in vivo efficacy testing for GFH009 will be performed by PIVOT investigators. "Participation in the NCI PIVOT Program provides an extensive and invaluable level of expertise in preclinical pediatric cancer testing and we are excited that we were granted this program after a diligent review process. In addition to being a source of non-dilutive funding for our GFH009 program, we also believe this discovery work could ultimately support a path to a rare disease pediatric voucher," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "We are optimistic that the significant anti-tumor activity of GFH009 recently demonstrated in in vitro and in vivo models will be mirrored in PIVOT's pediatric studies, allowing us to further expand our GFH009 clinical development program to include pediatric tumor types," continued Dr. Stergiou.

08:34 EST BioSig Technologies announces peer-reviewed case report on PURE EP system - BioSig Technologies announced that a peer-reviewed case report titled, "Confirmation of Acute Pulmonary Vein Reconnection with The Utilization of PURE EP's High-Frequency Algorithm" has been published in the Journal of Atrial Fibrillation & Electrophysiology. Co-authored by Roy Chung, MD, Clinical Cardiac Electrophysiologist at Cleveland Clinic and Zachary Koch, CCDS, CEPS, Clinical Director at BioSig Technologies, Inc., the case report describes a 65-year-old patient with a medical history of symptomatic and persistent atrial fibrillation undergoing pulmonary vein isolation. PURE EP's HFA signal analysis was observed alongside the simultaneous signal anno New Primary Logo New Primary Logotation produced by a 3D mapping system. PURE EP's real-time HFA identified early local activation, providing a clear and precise location that served as the primary target for ablation therapy during the procedure. Results from the case study support the efficacy of PURE EP's HFA in identification of the pulmonary vein gap compared to the inferior annotation produced by the 3D mapping system. "This case study adds to the growing pipeline of clinical evidence validating the PURE EP System as an essential and valuable technology for today's EP lab-particularly for challenging cases," commented Gray Fleming, Chief Commercial Officer, BioSig Technologies, Inc. "We believe that these findings, along with other clinical applications we continue to explore in collaboration with the Cleveland Clinic, demonstrate PURE EP's ability to set new standards in the field of electrophysiology."

08:32 EST Phunware to launch Smart Hospitality Solution at Wailea Bach Resort - Phunware (PHUN) announced that its Smart Hospitality Solution is being launched at Wailea Beach Resort - Marriott, Maui, which is part of the Marriott International (MAR). "Marriott is leading the way when it comes to tech-enabling guest experiences in a mobile-first world, so we are thrilled to partner with the forward-thinking team at Wailea Beach Resort to launch our Smart Hospitality Solution," said Randall Crowder, COO of Phunware. "By enabling guests to easily navigate every aspect of such an amazing property, we hope to ensure they have an opportunity to discover all of the amazing amenities Wailea Beach Resort has to offer."

08:30 EST Equinox Gold sells Solaris Resources shares for C$70.4M - Equinox Gold (EQX) has sold an aggregate 11M common shares of Solaris Resources (SLSSF) in the ordinary course for investment purposes through the facilities of the Toronto Stock Exchange through block trades for aggregate gross proceeds of C$70.4M. As a result of the transaction, including any exercise of the warrants, Equinox Gold's ownership has decreased to less than 10% of the issued and outstanding common shares of Solaris and Equinox Gold has ceased to be a "reporting insider". Accordingly, Equinox Gold will no longer file insider or early warning reports in respect of its ownership of securities of Solaris, except as required by applicable law. Equinox Gold remains a supportive shareholder of Solaris and does not currently plan to make any additional changes to its interest. Pursuant to the Transaction, Equinox Gold has agreed not to sell any of its remaining Solaris securities for 120 days.

08:27 EST Fastenal reports November sales up 10.2% to $577.83M - The company reported November sales of $577.83M versus $524.17M in the same month of last year. Fastenal reported November daily sales of $27.52M, up 10.2% versus 2021. Reference Link

08:26 EST Siyata Mobile adds RadioTrader as distributor for SD7 devices, VK7 accessories - Siyata Mobile has added RadioTrader, the UK and Ireland's premier two-way radio supplier, to distribute the SD7 ruggedized, mission critical PoC device and VK7 vehicle kit accessary.

08:25 EST Roth CH Acquisition IV Co trading halted, news pending

08:21 EST Oxford Lane estimates NAV per share $4.79-$4.89 as of November 30 - Management's unaudited estimate of the range of the NAV per share of common stock as of November 30, 2022 is between $4.79 and $4.89. This estimate is not a comprehensive statement of our financial condition or results for the month ended November 30, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending December 31, 2022 may differ materially from this estimate, which is given only as of November 30, 2022. As of November 30, 2022, the Company had approximately 163.5 million shares of common stock issued and outstanding.

08:20 EST Fortune Brands highlights go-forward strategy at investor day - Fortune Brands will host an Investor Day in advance of its planned separation into two companies, which is expected to occur on December 14. Shortly after the separation of MasterBrand, Fortune Brands will be changing its name to Fortune Brands Innovations. As Fortune Brands and MasterBrand prepare to pursue independent paths, members of the senior leadership teams of both companies will present an update on each company's strategic initiatives, growth plans and value creation drivers. In the morning session, Fortune Brands CEO Nicholas Fink and his leadership team will explain Fortune Brands' pursuit of supercharged categories. "I am thrilled to introduce Fortune Brands Innovations, a brand, innovation and channel leader in the home, security and commercial building markets. With leading positions in attractive growth markets, an aligned organization underpinned by the Fortune Brands Advantage capabilities that position us to drive exceptional returns, and a talented team with a track record of through-the-cycle value creation, we are well positioned to drive supercharged growth," said Fink. "Our focus on safety and sustainability, our ongoing digital transformation, and our disciplined approach to strategic acquisitions also set the stage for further long-term value creation. Taken together, I'm incredibly excited about the path forward for Fortune Brands Innovations." In the afternoon session, David Banyard, president and incoming CEO of MasterBrand, together with his leadership team, will elaborate on how MasterBrand is driving efficiency and flexibility. Banyard stated, "I am honored to lead MasterBrand, a company grounded in 70 years of rich history, as it starts a new chapter as an independent company. Our strategic transformation has enabled us to make great progress across our product lines and operations and we see tremendous opportunities ahead. Further evolution of The MasterBrand Way is helping us align the business for growth, engage teams to foster problem solving, and use technology to improve quality and service." He added, "With an unrivaled product offering, distribution network and operations, we are charting a course to deliver long-term sustainable growth while we strengthen our leadership position as the largest residential cabinet manufacturer in North America." In addition, both companies will provide an update on expectations for 2023 and outline future financial targets.

08:18 EST H2O Innovation granted first blue loan of $65M to fund growt - H2O Innovation has collaborated with National Bank of Canada to develop a sustainable financing solution to fund the Corporation's continued growth in water technology manufacturing and services by structuring its first Blue Loan. In addition, the Corporation increased its revolving credit facility by $10 M. The credit facility now stands at $65 M. H2O Innovation's inaugural Blue Loan has been inspired by the Guidelines for Blue Finance developed by the International Finance Corporation in January 2022. "Everything we do on a daily basis, from the engineering and manufacturing of water reuse plants to the operation of water assets and the supply of green chemicals and components to the desalination industry, is done to help solve water issues for good. We are very proud that H2O Innovation has obtained its inaugural Blue Loan from National Bank of Canada. Part of our mission is to drive intelligent solutions to help solve the growing challenges related to water use. The combination of population growth, aging infrastructure, regulatory frameworks driven by higher environmental standards, water scarcity, and an aging workforce drives growth for us and our industry. The support of National Bank of Canada serves as a reminder of the importance of investing in the water sector to ensure the sustainability of this vital resource," said Frederic Dugre, President and Chief Executive Officer of H2O Innovation. The Blue Loan will allow H2O Innovation to continue to evolve as a leader in water and wastewater technologies and services and to achieve its sustainability objectives, including reducing global water stresses and carbon emissions throughout their value chain.

08:17 EST Genetic Technologies publishes paper on geneType Multi-Risk test - Genetic Technologies announces the publication of a peer-reviewed paper describing the development and validation of the polygenic risk scores that underlie the risk predictions for cardiovascular diseases and type 2 diabetes in the geneType Multi-Risk Test. The paper titled "Polygenic risk scores for cardiovascular diseases and type 2 diabetes." Publication highlights: The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes. The cutting-edge study design meant that the polygenic risk scores developed by GTG use just the genetic changes essential to predict risk without sacrificing predictive performance compared with polygenic risk scores that use up to 820 times the number of genetic changes. This study used data from over 50,000 participants in the UK Biobank. GTG quantified the true effects of the polygenic risk scores in predicting disease by accounting for age and sex in the study design. The research team used a sophisticated sampling strategy that enabled the true performance of the polygenic risk score to be determined and not be influenced by the effects of age and sex. Genetic Technologies' CEO, Simon Morriss, said, "Implementation of risk assessment tests, such as our geneType Multi-Risk Test, that accurately predict the risk of a patient developing one of these serious diseases, will enable early intervention with great potential for improved patient outcomes".

08:14 EST FactSet, BMLL Technologies collaborate to analytics in the cloud - FactSet announced its collaboration with BMLL Technologies to offer the company's granular order book history and analytics in the cloud. The initial release of the FactSet-BMLL offering includes "Market by Price" Level 2 Tick History, which addresses the data quality challenges with current industry Level 2 offerings. By building upon BMLL's leading historic Level 3 data engineering capabilities, FactSet is bringing a best-in-class Level 2 product to market, equipping clients with deep market insights and real-time data. The collaboration represents a continuation of FactSet's strategy to provide innovative cloud solutions that help clients modernize and improve their market data technology and reinforces the company's commitment to expand its real-time data and tick history capabilities. Through the joint solution with BMLL, clients can now access Level 2 Data via the same symbology and APIs as the Level 1 Tick History on a common delivery platform to accelerate research, optimize workflow and trading strategies, and generate alpha at speed and scale.

08:13 EST Siemens, BWP, LiCAP partner for dry electrode manufacturing equipment - BW Papersystems, LiCAP and Siemens announce that they have entered a strategic partnership to manufacture and commercialize innovative dry electrode manufacturing systems for the battery cell industry. The strategic partnership between BW Papersystems, LiCAP and Siemens will make the North American and European Gigafactories more competitive through industrialization of LiCAP's cost-effective and sustainable Activated Dry Electrode technology. As a crucial manufacturing partner, Siemens will be integral in scaling production for both companies.

08:10 EST Incannex expands intellectual property position over IHL-42x - Incannex Healthcare announces the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea, OSA. With this latest provisional patent application, Incannex intends to pursue additional patent protection for its IHL-42X clinical program, consistent with the Company's ongoing commercial strategy to accrue a patent position across the development, manufacture, and use of the Company's drug candidates. IHL-42X was designed to combine two drugs, tetrahydrocannabinol and acetazolamide, with therapeutic effects on OSA that act via different mechanisms. Acetazolamide induces metabolic acidosis, raises the drive to breathe and reduces the sensitivity of body system that controls breathing, which helps to reduce the incidence and severity of apnoeas and hypopnoeas. CEO and Managing Director of Incannex Healthcare, Joel Latham said; "Incannex works closely with its patent attorneys to build upon its competitive position through the ongoing development of intellectual property assets. Our intention is to build patent families around our drug candidates as we learn more about them through our research and development programs undertaken by our dedicated scientific teams."

08:10 EST Leidos collaborates with Microsoft to synchronize warfighting technologies - Leidos LDOS) and Microsoft (MSFT) demonstrated a critical step in the realization of Joint All-Domain Command and Control through demonstrations during the U.S. Army's Project Convergence 22 experimentation exercises. The demonstration paired Leidos Edge to Cloud technology with the Microsoft Azure Cloud infrastructure to connect disparate legacy systems and new systems. The joint solution enables the rapid fielding of advanced software, applications, and security solutions within challenging operational environments. Leidos and Microsoft continue to work together with a focus on bringing warfighting capabilities to both strategic and tactical levels.

08:08 EST Akeso announces collaboration, license agreement with Summit Therapeutics - Akeso announced a collaboration and license agreement with Summit Therapeutics to out-license its breakthrough bispecific antibody, ivonescimab for development and commercialization in the United States, Canada, Europe, and Japan. In addition, the company will co-brand the product in the License Territories. Under the terms of the Agreement, Akeso will receive $500M upfront payment and the total potential deal value is up to $5B including regulatory and commercial milestone payments. Akeso will also receive low double-digit percentage of royalties on net product sales of ivonescimab. The Summit will receive the exclusive rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. Akeso will retain development and commercialization rights for the rest of the world including China. In addition, Dr. Michelle Xia will be appointed as one member of the board of directors of Summit. The deal is subject to customary closing practices, including applicable waiting periods under the Hart-Scott-Rodino Act.

08:07 EST FuelCell accepting orders for solid oxide electrolysis, fuel cell platform - FuelCell Energy announced it is accepting orders for its solid oxide electrolyzer and solid oxide fuel cell platform. The platform will give more organizations the option to implement a flexible energy strategy in order to: Start their energy transition today knowing they can shift to 100% zero-carbon hydrogen in the future. Produce clean hydrogen for use or storage from zero-carbon renewable or nuclear power, managing the peaks and valleys of renewables and providing flexibility to nuclear energy production. Create energy from any combination of available sources - from renewables, hydrogen, biogas, or natural gas. Provide continuous power and reduce grid dependence, co-locating generation and use wherever possible.

08:06 EST Trinity Capital announces joint venture - Trinity Capital entered into an agreement to co-manage a newly formed joint venture, i40, with certain funds and accounts managed by a specialist credit manager with over $5B of AUM. The JV will invest in loans and equipment financings to growth-stage companies that have been originated by Trinity. The initial capital commitment to the JV is $171.4M, consisting of a $21.4M commitment from Trinity and a $150.0M commitment from certain funds and accounts managed by the specialist credit manager. The JV intends to enter into a credit facility to leverage its assets in order to enhance returns and create additional deployment capacity.

08:04 EST CareDx announces $50M share repurchase plan - CareDx announced that its board of directors has authorized a common stock repurchase program of up to $50M of shares over a period of up to 24 months. Under the repurchase program, CareDx may purchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques. The timing and number of shares repurchased, and the price of any repurchases, will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The repurchase program does not obligate CareDx to acquire a specified number of shares and may be modified, suspended, or discontinued at any time at CareDx's discretion. Repurchases under this program will be funded from CareDx's existing cash and cash equivalents or future cash flow.

08:04 EST EDAP TMS appoints Ken Mobeck as CFO of EDAP Technomed - EDAP TMS SA (EDAP) hired Ken Mobeck as CFO of EDAP Technomed Inc., the Company's U.S. subsidiary. Prior to joining EDAP Technomed, Ken served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Incorporated (ARAY).

08:02 EST AbbVie collaborates with HotSpot Therapeutics for autoimmune diseases - AbbVie and HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases. HotSpot will receive an upfront cash payment of $40M and may be eligible to receive up to $295M in option fees and research and development milestones, with potential for further commercial milestones as well as tiered royalties on global net sales. Should AbbVie exercise its option to license, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for the IRF5 inhibitor program. In addition, HotSpot would have a one-time option to share in global R&D costs in exchange for increased royalty payments.

07:57 EST Astronics rises after Bell Textron wins Army's FLRAA contract - Shares of Astronics (ATRO) are up 59c, or 7%, to $9.59 after Bell Textron announced it has been awarded the development contract for the U.S. Army's Future Long-Range Assault Aircraft, or FLRAA, program. The award is based on Bell's V-280 Valor tiltrotor that was developed and tested as part of the Joint Multi-Role Technology Demonstrator program that began in 2013, the Textron (TXT) company stated. Previously, Bell Textron announced that it had selected Rolls-Royce and Astronics to support the Future Long-Range Assault Aircraft program in a collaboration to "focus on offering a low-risk and reliable integrated propulsion solution to the army." Reference Link

07:53 EST Lantheus announces pricing of offering of $500M convertible senior notes - Lantheus Holding announced the pricing of $500 million in aggregate principal amount of the Company's convertible senior notes due 2027. The Notes are being sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also granted the initial purchasers of the Notes an option to purchase, within the 13-day period beginning on, and including, the initial closing date of the offering, up to an additional $75 million in aggregate principal amount of Notes. The sale of the Notes to the initial purchasers is expected to settle on or about December 8, 2022, subject to customary closing conditions, and is expected to result in approximately $485 million in net proceeds to the Company, after deducting the initial purchaser's discount and estimated offering expenses payable by the Company. The Notes will be senior unsecured obligations of the Company. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Lantheus Medical Imaging, Inc., a direct wholly owned subsidiary of the Company. The Notes will bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027, unless earlier redeemed, repurchased or converted. The initial conversion rate for the Notes is 12.5291 shares of the Company's common stock per $1,000 in principal amount of Notes. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company's common stock, or a combination of cash and shares of the Company's common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company's common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The Company's board of directors has authorized the repurchase of up to $150 million in aggregate amount of its common stock under certain circumstances. The Company expects to use approximately $75 million of the net proceeds from the offering of the Notes to repurchase shares of its common stock from purchasers of Notes in this offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The Company expects the purchase price per share of the common stock repurchased in such transactions to equal the closing sale price per share of its common stock on December 5, 2022, which was $56.01 per share. These repurchases could increase, or prevent a decrease in, the market price of the Company's common stock or the Notes concurrently with the pricing of the Notes, and could result in a higher effective conversion price for the Notes. The Company intends to use the remainder of the net proceeds from the offering of the Notes for general corporate purposes, including other repurchases of its common stock from time to time in an amount up to $75 million, working capital, capital expenditures, refinancing or repaying debt, payments related to the previously announced license and collaboration agreements with POINT Biopharma Global Inc. and with an affiliate thereof if the transactions contemplated by such agreements are consummated, potential acquisitions and strategic transactions.

07:48 EST Vivint Smart Home jumps 32% to $11.86 after NRG Energy buyout offer - NRG Energy is down 8% to $37.55 pre-market on the news.

07:44 EST TSMC to triple U.S. chip investment to $40B - TSMC announced that in addition to TSMC Arizona's first fab, which is scheduled to begin production of N4 process technology in 2024, TSMC has also started the construction of a second fab which is scheduled to begin production of 3nm process technology in 2026. The overall investment for these two fabs will be approximately $40B, representing the largest foreign direct investment in Arizona history and one of the largest foreign direct investments in the history of the United States. In addition to the over 10,000 construction workers who helped with construction of the site, TSMC Arizona's two fabs are expected to create an additional 10,000 high-paying high-tech jobs, including 4,500 direct TSMC jobs. When complete, TSMC Arizona's two fabs will manufacture over 600,000 wafers per year, with estimated end-product value of more than $40B. In line with TSMC's commitment to green manufacturing, it was also revealed that TSMC Arizona is in the planning stages for an on-site Industrial Water Reclamation Plant that when finished, will allow the TSMC Arizona site to achieve near zero liquid discharge. Reference Link

07:35 EST Curo Group appoints Ismail Dawood as CFO, effective January 3 - CURO Group Holdings announced that it has appointed Ismail Dawood as Chief Financial Officer, effective January 3. He succeeds Roger Dean, who recently retired. Tamara Schulz, who has served as CURO's Interim Chief Financial Officer, will return to her role as Chief Accounting Officer.

07:34 EST ARway engages Stockhouse financial portal - Evan Gappelberg, CEO of ARway commented, "We are looking forward to increasing investors awareness and working with the team at Stockhouse.com to showcase ARway's groundbreaking no-code, no beacon spatial computing platform that is disrupting the AR wayfinding market!" ARway has engaged the services of Stockhouse with a 12 month contract for $72,000.

07:33 EST Shawcor acquires Kanata Electronic Services, terms not disclosed - Shawcor announced that it has acquired Kanata Electronic Services, a privately owned manufacturer and supplier of specialty cable assemblies and wire harnesses for the nuclear and aerospace industries. Kanata serves customers around the globe from a single, Toronto area site and will be integrated into Shawcor's ShawFlex wire and cable business. While Kanata primarily serves the nuclear and spacecraft industries with highly sophisticated, custom cable assemblies, it is also a recognized leader in the design, manufacture and supply of specialty cable and wire harness solutions for the military, medical and commercial industries. In the first nine months of 2022, Kanata generated approximately $3M in revenue. Terms of the transaction will remain private.

07:32 EST Virax Biolabs supplier receives EUA from FDA for COVID-19 Rapid Antigen Test - Virax Biolabs announced that their supplier has received an Emergency Use Authorization from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test. The Tests are ready for sale in the U.S. by Virax. Additionally, another Point of Care Rapid Antigen test to be distributed by Virax is seeking an approval with Health Canada for Canadian distribution. The Tests have been eligible for sale in markets accepting the CE Mark since 2020.

07:30 EST Gossamer Bio announces TORREY study meets primary endpoint - Gossamer Bio announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension, or PAH. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRa/ss, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension. The Phase 2 TORREY study enrolled 86 patients with WHO Functional Class, or FC, II or III PAH, with 42 randomized to the placebo arm and 44 randomized to the seralutinib arm. The primary endpoint of the study was change from baseline to Week 24 in pulmonary vascular resistance, or PVR. The secondary endpoint was change in six-minute walk distance, or 6MWD, from baseline to Week 24. Patients remained on their background PAH therapies during the study. At baseline, 57% of patients were on background triple therapy, consisting of three classes of vasodilator treatments. The mean baseline PVR and 6MWD of randomized patients were ~669 dynes*s/cm5 and ~408 meters, respectively. The treatment and placebo arms were generally well balanced, except for baseline WHO Functional Class: 20 FC II and 22 FC III patients were randomized to the placebo arm, while 30 FC II and 14 FC III patients were randomized to the seralutinib arm.

07:22 EST Wabtec's adaptive wheel slide protection solution gets certification - "Wabtec DistanceMaster solution took a major step toward improving braking performance for transit rail operators with the certification of the company's adaptive wheel slide protection WSP technology," stated the company. The solution addresses the wheel and rail adhesion bottleneck enabling transit systems to improve efficiency and increase network capacity. The company obtained the conformity certifications and the Interoperability Constituent certification from RINA following extensive tests in laboratory and operational environments. Wabtec conducted the laboratory tests at Deutsche Bahn Systemtechnik's accredited lab in Minden, Germany. The company also worked with Eurailtest, an accredited laboratory, to test the adaptive wheel slide protection technology in an operational environment on an SNCF Regiolis train.

07:21 EST Signet Jewelers jumps 7% to $62.00 after Q3 beat, FY23 guidance raised

07:18 EST Laser Photonics receives order from Baltimore Gas and Electric, no terms - Laser Photonics announced it received an order from Baltimore Gas and Electric BGE , in Baltimore, MD. Wayne Tupuola, chief executive officer of Laser Photonics, commented: "Baltimore Gas and Electric commissioned Laser Photonics to provide a handheld laser cleaning system for paint removal from various tank surfaces. Our CleanTech 2000 JobSite system was a strong choice as a safe, cost-efficient, high-quality answer for this and other applications." CleanTech 2000-CTH JobSite

07:16 EST Quhuo, FLJ Group sign cooperation framework agreement - FLJ Group signed a cooperation framework agreement with Quhuo. Under the Agreement, two parties will establish a continuing, stable and solid joint partnership and work together to provide their respective customers with integrated services across areas such as apartment rental, community service and platform development and expansion. Leveraging its large apartment network, the Company will provide customized rental apartments to Quhuo's large workforce to address their housing needs. On the other hand, Quhuo will provide comprehensive value-adding services such as delivery, cleaning and facilities maintenance to the Company's tenants. Looking forward, both parties are confident that they will be able to optimize their respective technology-driven and platform-based strength in workforce operational solutions and rental solutions and solidify their leading positions in respective fields. Working closely together, both parties will continue to provide more comprehensive services to their customers and achieve growth mutually.

07:14 EST Sernova CEO Philip Toleikis to transition to CTO - Sernova Corp. announced that, as part of a planned leadership succession process, and after a successful 13-year tenure, Dr. Philip Toleikis, President and CEO will be appointed Sernova's Chief Technology Officer. To achieve a seamless transition and continue progress on all Company activities, Dr. Toleikis will remain in the CEO role during the search period and continue to work closely with Executive Chair, Frank Holler. Mr. Holler will, in particular, take a leadership role and work closely with Dr. Toleikis in advancing Sernova's business development and corporate finance activities during the search period. The Company has engaged Slone Partners, an executive search firm with offices in Boston, San Francisco and Washington, D.C., to assist the Board of Directors in the hiring of the new CEO.

07:13 EST Lucira Health, Loch Lomond announce study on Lucira COVID-19 & Flu Test - Lucira Health and Loch Lomond Villa announced a clinical study to simultaneously test residents, medical and support staff, and visitors for COVID-19 and Influenza A/B infection with the Lucira COVID-19 & Flu Test. This pilot will enhance testing and tracking capabilities at Loch Lomond Villa, while allowing medical staff to conduct a comparative and observational study that will help assess the effectiveness of Lucira's testing platform in managing and minimizing COVID-19 and Influenza A/B outbreaks in long-term care settings. "Lucira's test means that Canadians no longer need to trade-off speed for accuracy when testing for infection," said Erik Engelson, President and Chief Executive Officer of Lucira Health. "This is the only portable molecular self-test for COVID-19 and the flu on the market, providing lab-quality test results, at home and work, in hospitals or while travelling."

07:11 EST Lithia & Driveway acquires Ferrari of Denver - Lithia & Driveway announced they have expanded into Colorado, purchasing Ferrari of Denver, the company's first Ferrari store. Ferrari of Denver will specialize in personalized, in-home customer experiences covering the full ownership lifecycle. The only Ferrari location in the greater Rocky Mountains region, this store boasts three Ferrari-certified technicians and a Bentley master-certified technician. In addition to Ferrari, this store also sells Bentley and other luxury brands. Located in Highlands Ranch, CO, this acquisition is projected to generate $75M in annualized revenue bringing LAD's total expected annualized revenue acquired in 2022 to over $3.3B. Acquisitions are a key part of the company's 2025 Plan to reach $50B in revenue and $55 to $60 in earnings per share.

07:11 EST Spectrum announces Rolvedon added to latest NCCN Guidelines - Spectrum announced that Rolvedon has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines, or NCCN Guidelines, in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia and now include Rolvedon as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery.

07:10 EST Enthusiast Gaming says Pocket Gamer Connects series drew record attendees - Enthusiast Gaming Holdings announces that its Pocket Gamer Connects live events series drew record attendees in 2022. PGC showcases how the world's largest game publishers and developers come together to learn, share, and grow the business of gaming with Enthusiast Gaming driving the conversation. Following more than two years of running successful virtual events in response to the Covid 19 pandemic, the gaming community proved its desire to reconnect in person in 2022. Across six PGC events in 2022 in London, Seattle, Toronto, Helsinki, Jordan, and last week in Riyadh, Saudi Arabia, a record 6,700+ industry attendees and nearly 1,000 gaming industry speakers and thought leaders connected and shared insights on a wide range of relevant topics including User Acquisition, Mastering Multiplayer, The Art of Publishing, Ad Insights, Blockchain Gaming, Developer Toolkit, CFO Insider, and more.

07:09 EST Telesat Holding, Sencinet enter five-year HTS capacity commitment - Telesat (TSAT) and Sencinet announced Sencinet's 5-year high-throughput satellite capacity commitment to modernize and expand the Petrobras (PBR) oil and gas connectivity network.

07:08 EST Equillium, Ono enter exclusive itolizumab option and asset purchase pact - Equillium and Ono Pharmaceutical announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium's rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the rights to commercialize itolizumab in the United States, Canada, Australia, and New Zealand. Under the terms of the agreement, Equillium will receive a non-refundable upfront payment of approximately $26M and will also be eligible to receive up to an aggregate of approximately $138.5M for exercise of the option and milestone payments from development through first commercial sale. Equillium will be responsible for the conduct of all research and development of itolizumab, which will be fully funded by Ono on a quarterly basis commencing July 1 through the option period. The option period will expire three months following delivery of topline data from the EQUALISE study in lupus nephritis and interim data from the EQUATOR Phase 3 study in acute GVHD.

07:06 EST Barnes & Noble Education sees FY23 adjusted EBITDA $20M-$30M - The company said, "For fiscal year 2023, the Company expects consolidated non-GAAP Adjusted EBITDA to be between $20 million to $30 million, representing non-GAAP Adjusted EBITDA growth of $25 million to $35 million compared to fiscal year 2022. The Company's Retail segment will be the primary driver of non-GAAP Adjusted EBITDA growth driven by new and ongoing First Day Complete course ware model implementations, growth within its general merchandise business, new business margin, and cost reductions."

07:05 EST Agios Pharmaceuticals appoints Tsveta Milanova as CCO - Agios Pharmaceuticals (AGIO) announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023. Ms. Milanova will succeed Richa Poddar, who has been with Agios since 2016 and will continue to serve as the company's chief commercial officer until the end of the year. Milanova spent five years at Alexion in high-impact commercial and market access roles, including senior vice president, head of U.S. commercial; senior vice president, global commercial strategy; and senior vice president, global value, access and policy.

07:04 EST Modine Coatings partners with Wright Sales - Modine Coatings, a division of Modine Manufacturing, is partnering with Wright Sales to expand access to the GulfCoat Contractor Series product line and the Insitu Spray Applied Coating Services. As part of the partnership, Wright Sales, a RectorSeal manufacturing representative, will market Insitu Spray Applied Coating Services and the complete line of GulfCoat Contractor Series products in California, Arizona, Nevada, New Mexico, Texas and Hawaii. The partnership will bring a dedicated focus to Modine Coating products and services for HVAC/R contractors to help maximize solutions in their respective markets.

07:02 EST Warner Bros. Discovery, Amazon.com: HBO Max available on Prime Video in U.S. - Warner Bros. Discovery (WBD) and Amazon (AMZN) announced that HBO Max is once again available on Prime Video Channels in the U.S. Prime customers can sign up for HBO Max for $14.99 per month. Subscribers will have access to 15,000 hours of curated premium content. Additionally, subscribers will have access to the expanded content offering that will be available in Warner Bros. Discovery's enhanced streaming service when it launches next year.

07:00 EST Sempra Energy subsidiary enters long-term sale and purchase agreement with Engie - Sempra Infrastructure, a subsidiary of Sempra, announced it has entered into a long-term sale and purchase agreement, or SPA, with Engie S.A. for the supply of liquefied natural gas, or LNG, from Phase 1 of its proposed Port Arthur LNG project under development in Jefferson County, Texas. Under the SPA, Engie has agreed to purchase approximately 0.875M tons per annum of LNG for 15 years, delivered on a free-on-board basis, and sourced from natural gas producers whose gas has been certified by an independent third party in accordance with environmental, social and governance performance criteria. The agreement also provides a framework to explore ways to lower the carbon intensity of LNG produced from the Port Arthur Phase 1 LNG project through GHG emission reduction, mitigation strategies and a continuous improvement approach.

06:57 EST AutoZone reports inventory up 17.6% y/y - The company's inventory increased 17.6% over the same period last year, driven by inflation and growth initiatives. Net inventory, defined as merchandise inventories less accounts payable, on a per store basis, was negative $249 thousand versus negative $207 thousand last year and negative $240 thousand last quarter.

06:50 EST Lazard names Ronald Temple as Chief Market Strategist - Lazard announced that Ronald Temple has been named Chief Market Strategist, effective immediately. In this newly created role, Temple will serve as a market strategist and thought leader to Lazard's Asset Management and Financial Advisory businesses and will work closely with the firm's new Geopolitical Advisory group. He will continue to provide macroeconomic and market perspectives to Asset Management's global client base and to its investment teams on a firmwide basis. Since joining Lazard Asset Management in 2001, Temple has held several high-profile investment and client-facing roles, including analyst and co-director of global research. Most recently, he has overseen U.S. equity and global equity strategies as well as Lazard's Multi-Asset platform.

06:47 EST SQZ Biotechnologies receives FDA Fast Track Designation for eAPC candidate - SQZ Biotechnologies announced that the U.S. FDA has granted Fast Track Designation for the company's Enhanced Antigen Presenting Cell candidate for the treatment of HPV16+ advanced or metastatic solid tumors. The company also presented clinical data from its ongoing Antigen Presenting Cells and eAPC clinical trials at the European Society for Medical Oncology Immuno-Oncology Congress. Data also demonstrated that its APC and eAPC therapeutic candidates were well-tolerated among patients treated in its trials. Manufacturing of the cell product took less than 24 hours, and the median viability of all lots, in both clinical trials, was greater than 90%. In the SQZ eAPC clinical trial, scans showed stable disease as the best overall response for two out of four evaluable patients in low dose Cohort 1. A positive ELISpot response for the E7 antigen was observed in one of these patients and correlated with prolonged stable disease. This patient remains on treatment.

06:41 EST Meta threatens to pull news from platform if Congress passes journalism bill - In a Monday tweet, Andy Stone, communications at Meta Platforms, posted the company's statement on the Journalism Competition and Preservation Act: "If Congress passes an ill-considered journalism bill as part of national security legislation, we will be forced to consider removing news from our platform altogether rather than submit to government-mandated negotiations that unfairly disregard any value we provide to news outlets through increased traffic and subscriptions. The Journalism Competition and Preservation Act fails to recognize the key fact: publishers and broadcasters put their content on our platform themselves because it benefits their bottom line - not the other way around. No company should be forced to pay for content users don't want to see and that's not a meaningful source of revenue. Put simply: the government creating a cartel-like entity which requires one private company to subsidize other private entities is a terrible precedent for all American businesses." Reference Link

06:37 EST Whitestone REIT provides update on disposition activities - Whitestone REIT has completed approximately $36M in property dispositions since 3Q22. The dispositions are part of the company's ongoing asset management strategy and resulted in net proceeds received of approximately $34M after prorations and transaction costs. The combined sales were completed at a capitalization rate of 5.6%, based on the 2022 annualized nine-month property net operating income of approximately $2.0M divided by sales price. Occupancy for the combined group stood at 90.3% while average base rent was $14.51.

06:36 EST X-energy to go public via merger with Ares Acquisition - X Energy Reactor Company, a developer of small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation announced that they have entered into a definitive business combination agreement. The business combination ascribes a pre-money equity value of approximately $2.0 billion to X-energy. Existing X-energy equity holders will roll 100% of their existing equity interests into the combined company. In addition, the combined company will receive approximately $1 billion of cash held in AAC's trust account, assuming no redemptions by AAC shareholders. Institutional and strategic investors have also invested or committed $120 million in financing. This includes an invested private round of financing, which comprises $30 million from Ares and $45 million from OPG and Segra Capital Management, a leading nuclear energy-focused hedge fund, as well as an additional commitment of $45 million from Ares to be invested concurrent with the closing of the transaction. X-energy also received approximately $58 million of interim financing throughout 2022 from existing strategic investors, including Dow and Curtiss-Wright Corporation. Immediately following the consummation of the transaction and assuming none of AAC's existing shareholders exercise their redemption rights, X-energy's existing equity holders are expected to hold over 60% of the issued and outstanding shares of common stock of the combined company. The Board of Directors of AAC and the Board of Directors of X-energy have both unanimously approved the proposed transaction. The proposed transaction has also been approved by the requisite members of X-Energy. Completion of the transaction is subject to customary closing conditions, including the approval of the AAC shareholders and the receipt of certain governmental and regulatory approvals. The transaction is expected to be completed in the second quarter of 2023. Upon the closing of the transaction, the combined company will be named X-Energy, Inc., and its common equity securities and warrants will be listed on the New York Stock Exchange.

06:29 EST F-star Therapeutics presents clinical data on antitumor activity of FS222 - F-star Therapeutics announced new clinical data from its potentially best-in-class clinical asset FS222, a CD137/PD-L1 targeting tetravalent bispecific antibody, at the European Society of Medical Oncology Immuno-Oncology Annual Congress in Geneva. In preclinical models, engagement of PD-L1 and CD137 by FS222 induced T cell proliferation and cytokine production that was associated with significant tumor regression compared to the combination of CD137 and PD-L1 targeting monospecific antibodies. Phase 1 interim efficacy and safety results on FS222 as of July 20: 33 patients had been treated to date with FS222; one non-squamous NSCLC, PD-L1 naive patient experienced a complete response at 8 weeks, at a dose of 1mg/kg. The CR has remained persistent for 40.9 weeks as of 20th July 2022. 6 patients had disease stabilization, 16 had progressive disease, 2 were discontinued before week 8, and 8 were awaiting their week 8 evaluation. FS222 showed a manageable safety profile with most adverse events Grade 1-2. One patient experienced a DLT of Grade 3 febrile neutropenia. No patients discontinued FS222 due to an AE. Maximum tolerated dose was not reached, and dose escalation is ongoing. The pharmacological activity was demonstrated by increased peripheral soluble target receptors and proliferating CD4+ and CD8+ T cells.

06:24 EST Standard Lithium signs key agreement for access to commercial lithium plant - Standard Lithium is pleased to announce it has completed all necessary agreements with LANXESS Corporation to secure access to the proposed commercial lithium plant site and conduct all required fieldwork to support the Definitive Feasibility Study underway. Standard Lithium is also pleased to report that subsequent to signing the Site Access Agreement, the company has commenced the site work necessary for the design of its first commercial lithium plant. Dr. Andy Robinson, President of Standard Lithium commented, "The company is pleased to reach this important milestone. Our team has successfully negotiated and agreed to a key agreement with Lanxess, the site owner, to exclusively secure the required property for our commercial facilities and allow us to start working on the ground at the proposed location of the first commercial lithium project. The data gathered over the next few months will be vital to allow the OPD team to design the plant and locate key equipment on the large land area available to Standard Lithium at Lanxess' South Plant facility. Once the important ground conditions are determined, and the location of key equipment can be fixed, then the engineering work to allow for connection between the Standard Lithium plant and Lanxess' existing brine infrastructure present at the site can begin. We look forward to announcing more developments as the design towards the company's first commercial lithium project unfolds."

06:19 EST Achilles Therapeutics' cNeT shows "encouraging" response in two cancer trials - Achilles Therapeutics presented an "encouraging" interim Phase I/IIa update on the use of clonal neoantigen reactive T cells - cNeT - from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer - NSCLC - and the THETIS study in recurrent or metastatic malignant melanoma at the ESMO Immuno-Oncology Congress 2022. "The partial response and stable disease observed with low doses of cNeT in this difficult to treat patient population are encouraging, and coupled with the well-tolerated safety profile, highlight a favorable therapeutic window to further dose escalate and help drive deeper, more durable responses," said Karl Peggs, Chief Medical Officer. Data summary: 14 patients treated - 8 NSCLC, 6 melanoma -; confirmed partial response and stable disease achieved with low doses of cNeT and reduced dose lymphodepletion and IL-2 in NSCLC; 1 partial response of 56% tumor reduction maintained at week 36 and 6 patients with stable disease with overall durable clinical benefit at 12 weeks in 71% of evaluable patients - 5/7- with advanced NSCLC; cNeT driven anti-tumor activity in the partial responder is supported by T cell engraftment and cytokine profiles; stable disease in 50% of evaluable patients - 3/6 - with melanoma; "encouraging" early safety and tolerability profile for cNeT; safety and tolerability observations of cNeT compare favorably to standard tumor infiltrating lymphocytes due to less IL-2 related toxicity. Lymphopenia and neutropenia were the most common adverse events and no dose limiting high-grade toxicities associated with IL-2 were reported. Effective lymphodepletion and subsequent immune reconstitution were observed in all patients despite lower doses of lymphodepleting agents.

06:16 EST Energous says 1W WattUp PowerBridge transmitter approved in South Korea - Energous announced that its 1W WattUp PowerBridge transmitter technology has been approved in South Korea for unlimited wireless power distance transmission for IoT applications. Energous' WattUp PowerBridge supports wireless power transfer for multiple next-generation applications including smart tags, electronic shelf labels, sensors, asset trackers and more.

06:13 EST Fresenius Medical Care CEO Carla Kriwet departs amid 'strategic differences' - In a Monday press release, Fresenius said Helen Giza has been appointed CEO of Fresenius Medical Care. Previously, she was Deputy CEO of Fresenius Medical Care. The Supervisory Board of Fresenius Medical Care Management AG unanimously appointed her to succeed Dr. Carla Kriwet, who will leave the company at her own request and by mutual agreement due to strategic differences. Helen Giza will continue to serve as CFO of Fresenius Medical Care until a successor is appointed for this position. In her capacity as CEO of Fresenius Medical Care, Ms. Helen Giza will also be a member of the Management Board of Fresenius Management SE. Dr. Carla Kriwet has resigned from her position as a member of the Management Board of Fresenius Management.

06:13 EST Acutus Medical receives CE Mark for AcQMap 3D Imaging and Mapping Catheter - Acutus Medical announced receipt of a CE Mark issued under the European Union Medical Device Regulations for its AcQMap 3D Imaging and Mapping Catheter, the world's only integrated high-resolution ultrasound imaging and non-contact mapping catheter. The EU MDR was established to create a more robust legislative framework to better protect public health and patient safety. Acutus will file for EU MDR approval for the remaining products in the company's portfolio to ensure compliance by the May of 2024 deadline. This will allow physicians to have long-term access to the company's full portfolio of differentiated mapping, ablation, and EP accessory products.

06:11 EST Acutus Medical receives CE Mark from EU MDR for AcQMap - Acutus Medical announced receipt of a CE Mark issued under the European Union, or EU, Medical Device Regulations, or MDR, for its AcQMap 3D Imaging and Mapping Catheter, the world's only integrated high-resolution ultrasound imaging and non-contact mapping catheter.

06:10 EST Emergent BioSolutions announces FDA acceptance of Narcan sNDA for review - Emergent BioSolutions announced that the FDA has accepted for review its supplemental new drug application, or sNDA, for Narcan Nasal Spray, as an over-the-counter, or OTC, emergency treatment for known or suspected opioid overdose. The application has been granted priority review by the FDA and, if approved, would be the first 4 mg naloxone nasal spray available OTC in the U.S. The Prescription Drug User Fee Act goal date is March 29, 2023.

06:08 EST Ocuphire Pharma submits NDA to FDA for Nyxol - Ocuphire Pharma announced the submission of a New Drug Application to the U.S. FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the reversal of pharmacologically-induced mydriasis produced by adrenergic agonist or parasympatholytic agents, or a combination thereof. Ocuphire has received the $35M upfront payment under the license agreement. Combined with its previous reported cash balance of $13.9M at Sept 30, 2022, the company believes that it has sufficient capital to fund operations into 2025, including advancing development of APX3330. If Nyxol is approved for RM in the US, Ocuphire is eligible to receive a $10M milestone payment.

06:05 EST NRG Energy to acquire Vivint Smart Home for $12 per share, or $2.8B cash - NRG Energy (NRG) and Vivint Smart Home (VVNT) announced they have entered into a definitive agreement under which NRG will acquire Vivint for $12 per share or $2.8B in an all-cash transaction with an implied multiple of 6.3x run-rate Enterprise Value to Adjusted EBITDA. The agreement has been unanimously approved by the boards of directors of both companies. NRG will acquire 100% of the outstanding equity of Vivint for a total transaction value of $5.2B, which consists of approximately $2.8B in cash and the assumption of $2.4B of debt (net of cash), which benefits from attractive terms and pricing. This consideration represents a premium of approximately 33% to Vivint's closing share price on December 5, 2022. NRG's capital allocation strategy will continue to opportunistically balance its growth, return of capital, and balance sheet objectives. NRG intends to complete its existing $1 billion share repurchase program over the near term, of which $360 million was remaining as of November 30, 2022. In 2023, NRG expects to use its excess free cash flow to fund the Vivint acquisition, reduce acquisition-related debt, and maintain its common stock dividend growth policy. In 2024, the Company intends to return to its 50% return of capital / 50% growth capital allocation policy. NRG remains highly committed to its dividend growth policy, which remains unchanged from previous guidance. Management remains committed to maintaining its strong balance sheet and credit ratings. The Company expects to achieve its investment grade credit metrics target of 2.50-2.75x Net Debt / Adjusted EBITDA by late 2025 to 2026 through the combination of debt reduction and growth. The transaction is expected to close in the first quarter of 2023 and is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon completion of the transaction, NRG intends to maintain a significant presence in Utah.

05:47 EST Daqo New Energy announces 5B polysilicon expansion project to increase capacity - Daqo New Energy announced that its Phase 5B polysilicon expansion project in Inner Mongolia is expected to increase the company's annual polysilicon production capacity by 100,000 MT to a total of 305,000 MT by the end of 2023. The company's existing polysilicon facilities in Xinjiang with nameplate capacity of 105,000 MT are expected to produce approximately 130,000 to 132,000 MT of polysilicon in 2022. The Phase 5A project with nameplate capacity of 100,000 MT in Inner Mongolia, currently under construction, is expected to be completed in Q2 2023. The newly announced Phase 5B project will add another 100,000 MT capacity and increase the company's total annual production capacity to 305,000 MT by the end of 2023. The capital expenditures for the Phase 5B project are estimated to be approximately RMB 9.2B.

05:42 EST Bombardier breaks ground on AUH service center - Bombardier announced the official groundbreaking of its new service center at Abu Dhabi International Airport, or AUH, in Abu Dhabi, United Arab Emirates, or UAE. The new facility is Bombardier's first full-service facility in the UAE and builds on its long-term commitment to our customers in this critical market. At full capacity, the new OEM-operated service facility will also add more than 100 aerospace jobs in the community, cementing Bombardier's presence in this key financial hub. The new facility is targeted to open in 2025 and once fully operational, should help Bombardier continue to expand and grow its aftermarket revenues beyond 2025. Bombardier's new Abu Dhabi Service Centre will feature a large hangar, comprehensive parts depot and a complete suite of maintenance services including scheduled and unscheduled heavy maintenance, aircraft modifications, paint modification, aircraft on ground capabilities, and aircraft parking services. The new facility will also have the capacity to fit up to four Global 7500 aircraft - and will be able to service the Bombardier Global 8000, when it enters into service in 2025. It will provide the ultimate maintenance solution for our in region and worldwide customers of Bombardier's Learjet, Challenger and Global aircraft families.

05:38 EST UMC reports November sales of NT$22.55M, up 14.67%

05:34 EST KKR has agreed to acquire Clinisupplies from Healthium, terms undisclosed - KKR has agreed to acquire Clinisupplies from Healthium. Clinisupplies' management team will continue to hold a minority position. Financial details of the transaction were not disclosed. Clinisupplies is a UK-based manufacturer and distributor of continence care products, including urinary collecting devices and catheters. Clinisupplies' products are supplied to hospitals and pharmacies, while also available for delivery to patients directly through its home delivery services - "Clinidirect." Clinisupplies is headquartered in Watford, London, and employs over 400 employees. Claus Bjerre, KKR senior advisor and former CEO of Atos Medical AB and former president, North America, of Coloplast, will serve as chairman of Clinisupplies' board of directors, where he will draw on his sector experience and help guide the group on its future growth. In addition to leveraging KKR's broader advisor and expert network, industry veteran Douglas Le Fort, who brings over 20 years of senior executive leadership experience, including as an executive committee member at ConvaTec Group, will also join the board of directors.

05:24 EST Mainz Biomed receives IRB approval for ReconAAsense protocol - Mainz Biomed announced that it has received approval from an independent Institutional Review Board, or IRB, for the protocol ReconAAsense, the company's U.S. pivotal study to evaluate the clinical performance of its highly efficacious and detection test for colorectal cancer, or CRC. Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the FDA to achieve marketing authorization. ReconAAsense is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States. The study objectives include calculating sensitivity, specificity, positive predictive value and negative predictive value in average-risk subjects for CRC and advanced adenomas. Integral to the Company's development strategy concerning the evolution of the product's specifications is the potential to upgrade its technical profile to achieve a transformational advancement in self-administered CRC screening. To this end, Mainz Biomed recently initiated eAArly DETECT, its U.S. extension of ColoFuture, the Company's European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into its next-generation product. These biomarkers have demonstrated a unique ability to identify precancerous colonic polyps and early-stage CRC (Herring et al., 2021). The eAArly DETECT study was initiated in November of 2022 and is evaluating the effectiveness of these biomarkers to enhance product specifications to extend its capability to include the detection of advanced adenomas while increasing rates of diagnostic sensitivity and specificity for colorectal cancer. Mainz Biomed expects to complete eAArly DETECT enrollment in Q1 2023 and targets reporting topline results in 1H 2023. Based on the study's outcome, Mainz Biomed will decide on the integration of the biomarkers evaluated in ColoFuture's eAArly DETECT into the ReconAAsense study.

05:14 EST Colliers acquires majority interest in BelSquare SRL, terms undisclosed - Colliers announced that it has acquired a majority interest in BelSquare SRL, the Belgium real estate advisor. This acquisition combines BelSquare with Colliers' Belgium team, adding to the services available to clients. Under the guidance of Antoine Derville, CEO of Colliers, France and Belgium, Charles Lasserre and David Vermeesch, who were Managing Partners of BelSquare, become co-heads of the newly formed Colliers Belgium operation. Other members of the leadership team include Annick Vandenbulcke, who as former managing director of Colliers Belgium will continue as head of occupier advisory, Colliers, Belgium. BelSquare is a 26-person multi-service business, acting for domestic and international occupier, owner and investor clients.

05:06 EST Ambarella announces first centralized 4D imaging radar architecture - Ambarella announced the world's first centralized 4D imaging radar architecture, which allows both central processing of raw radar data and deep, low-level fusion with other sensor inputs-including cameras, lidar and ultrasonics. This breakthrough architecture provides greater environmental perception and safer path planning in AI-based ADAS and L2+ to L5 autonomous driving systems, as well as autonomous robotics. It features Ambarella's Oculii radar technology, including the only AI software algorithms that dynamically adapt radar waveforms to the surrounding environment-providing high angular resolution of 0.5 degrees, an ultra-dense point cloud up to 10s of thousands of points per frame and a long detection range up to 500+ meters. All of this is achieved with an order of magnitude fewer antenna MIMO channels, which reduces the data bandwidth and achieves significantly lower power consumption than competing 4D imaging radars. Ambarella's centralized 4D imaging radar with Oculii technology provides a flexible and high performance perception architecture that enables system integrators to future proof their radar designs.